<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Citalopram</title><meta name="description" content="Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems. Approved in 1998, citalopram is marketed under the brand name Celexa..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Celexa"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Citalopram"/><meta property="og:title" content="Citalopram"/><meta property="og:description" content="Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems. Approved in 1998, citalopram is marketed under the brand name Celexa..."/><meta property="og:url" content="https://grokipedia.com/page/Citalopram"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Citalopram"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:45.355Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Citalopram"/><meta name="twitter:description" content="Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems. Approved in 1998, citalopram is marketed under the brand name Celexa..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="91beb7058afd80625b47da80d2ab2c06-3b5f5a45b64e5dcb-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=91beb7058afd80625b47da80d2ab2c06,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.8332972958420084,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#citalopram" class="transition-opacity hover:opacity-100 opacity-50">Citalopram</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#chemical-structure-and-stereochemistry" class="transition-opacity hover:opacity-100 opacity-50">Chemical Structure and Stereochemistry</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mechanism-of-action" class="transition-opacity hover:opacity-100 opacity-50">Mechanism of Action</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics-and-metabolism" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics and Metabolism</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-efficacy-and-evidence" class="transition-opacity hover:opacity-100 opacity-50">Clinical Efficacy and Evidence</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#evidence-for-major-depressive-disorder" class="transition-opacity hover:opacity-100 opacity-50">Evidence for Major Depressive Disorder</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#evidence-for-anxiety-disorders-and-other-conditions" class="transition-opacity hover:opacity-100 opacity-50">Evidence for Anxiety Disorders and Other Conditions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#comparative-effectiveness-limitations-and-critiques" class="transition-opacity hover:opacity-100 opacity-50">Comparative Effectiveness, Limitations, and Critiques</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-uses" class="transition-opacity hover:opacity-100 opacity-50">Clinical Uses</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#approved-indications" class="transition-opacity hover:opacity-100 opacity-50">Approved Indications</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#off-label-applications" class="transition-opacity hover:opacity-100 opacity-50">Off-Label Applications</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#administration-and-dosage" class="transition-opacity hover:opacity-100 opacity-50">Administration and Dosage</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#dosing-guidelines" class="transition-opacity hover:opacity-100 opacity-50">Dosing Guidelines</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#formulation-and-pharmacotherapeutic-considerations" class="transition-opacity hover:opacity-100 opacity-50">Formulation and Pharmacotherapeutic Considerations</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#safety-profile" class="transition-opacity hover:opacity-100 opacity-50">Safety Profile</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#common-adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Common Adverse Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#serious-risks-including-suicidality" class="transition-opacity hover:opacity-100 opacity-50">Serious Risks Including Suicidality</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#long-term-effects-and-discontinuation" class="transition-opacity hover:opacity-100 opacity-50">Long-Term Effects and Discontinuation</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#drug-interactions" class="transition-opacity hover:opacity-100 opacity-50">Drug Interactions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#major-interactions" class="transition-opacity hover:opacity-100 opacity-50">Major Interactions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#serotonin-syndrome-and-related-risks" class="transition-opacity hover:opacity-100 opacity-50">Serotonin Syndrome and Related Risks</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#use-in-special-populations" class="transition-opacity hover:opacity-100 opacity-50">Use in Special Populations</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pregnancy-lactation-and-reproductive-effects" class="transition-opacity hover:opacity-100 opacity-50">Pregnancy, Lactation, and Reproductive Effects</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pediatrics-and-adolescents" class="transition-opacity hover:opacity-100 opacity-50">Pediatrics and Adolescents</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#elderly-and-overdose-scenarios" class="transition-opacity hover:opacity-100 opacity-50">Elderly and Overdose Scenarios</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history-and-development" class="transition-opacity hover:opacity-100 opacity-50">History and Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#discovery-and-clinical-trials" class="transition-opacity hover:opacity-100 opacity-50">Discovery and Clinical Trials</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#regulatory-approvals-and-patent-issues" class="transition-opacity hover:opacity-100 opacity-50">Regulatory Approvals and Patent Issues</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#societal-and-regulatory-context" class="transition-opacity hover:opacity-100 opacity-50">Societal and Regulatory Context</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prescribing-trends-and-market-dynamics" class="transition-opacity hover:opacity-100 opacity-50">Prescribing Trends and Market Dynamics</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#controversies-including-overprescription-and-public-health-debates" class="transition-opacity hover:opacity-100 opacity-50">Controversies Including Overprescription and Public Health Debates</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="citalopram" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Citalopram<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">
Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_60qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Approved in 1998, citalopram is marketed under the brand name Celexa and exists as a racemic mixture of R- and S-enantiomers, with the S-enantiomer (escitalopram) demonstrating greater potency at the serotonin transporter.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Clinical trials have established its efficacy in alleviating depressive symptoms, outperforming placebo in reducing Hamilton Depression Rating Scale scores and preventing relapse in maintenance therapy, particularly among elderly patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> However, its use has been associated with dose-dependent QT interval prolongation, prompting FDA warnings against doses exceeding 40 mg daily due to risks of torsades de pointes and sudden cardiac death, alongside a black box warning for heightened suicidality risk in pediatric and young adult populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Common adverse effects include nausea, dry mouth, somnolence, and sexual dysfunction, reflecting its serotonergic profile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_100qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="pharmacology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="chemical-structure-and-stereochemistry" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Chemical Structure and Stereochemistry<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram has the molecular formula Câ‚‚â‚€Hâ‚‚â‚FNâ‚‚O and the IUPAC name 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_42qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Its core scaffold is a 1,3-dihydro-2-benzofuran (isobenzofuran) ring system bearing a cyano substituent at the 5-position and, at the 1-position, both a 4-fluorophenyl group and a 3-(dimethylamino)propyl side chain.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_82qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> This 1-position carbon serves as the sole stereogenic center.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The pharmaceutical formulation of citalopram is administered as a 1:1 racemic mixture of its (R)- and (S)-enantiomers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The (S)-(+)-enantiomer, escitalopram, exhibits substantially higher potency in inhibiting serotonin reuptake compared to the (R)-(-)-enantiomer, which demonstrates over 100-fold lower affinity for the serotonin transporter.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The (R)-enantiomer exerts minimal direct serotonergic effects but can allosterically antagonize the activity of the (S)-enantiomer, potentially diminishing overall efficacy in the racemate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> This stereoselective pharmacology underpins the development of escitalopram as a purified enantiomer for enhanced therapeutic profile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<h3 id="mechanism-of-action" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mechanism of Action<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram is a selective serotonin reuptake inhibitor (SSRI) that primarily exerts its pharmacological effects by blocking the serotonin transporter (SERT, encoded by <em>SLC6A4</em>), thereby inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft into presynaptic neurons.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> This action increases extracellular serotonin concentrations in the central nervous system, potentiating serotonergic neurotransmission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> The antidepressant efficacy of citalopram is presumed to stem from this enhancement of serotonergic activity, though the precise downstream adaptations required for therapeutic effectsâ€”such as desensitization of presynaptic 5-HT<sub>1A</sub> autoreceptors and alterations in postsynaptic receptor signalingâ€”remain incompletely elucidated and occur over weeks despite rapid SERT occupancy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_q4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram demonstrates high affinity for SERT (inhibition constant <em>K</em><sub>i</sub> approximately 1â€“10 nM for the active enantiomer), with substantially lower affinity for norepinephrine (NET) and dopamine (DAT) transporters (<em>K</em><sub>i</sub> &gt;1,000 nM), conferring its selectivity as an SSRI over other monoamine transporters.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i4qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> At therapeutic concentrations, it exhibits minimal direct interactions with serotonin receptors (e.g., 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>) or other neurotransmitter systems, though weak antagonism at histamine H<sub>1</sub> and muscarinic receptors has been noted at higher doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_124qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Additionally, citalopram binds to an allosteric site on SERT distinct from the orthosteric (primary substrate/inhibitor) site, which modulates inhibitor binding kinetics, reduces dissociation rates, and may contribute to its sustained inhibition of serotonin uptake.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_164qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_184qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As a racemic mixture of (R)- and (S)-enantiomers, citalopram&#x27;s SSRI activity is predominantly attributable to the (S)-enantiomer (escitalopram), which inhibits serotonin uptake with approximately 167-fold greater potency than the (R)-enantiomer (IC<sub>50</sub> values of ~0.6 nM versus ~100 nM, respectively).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_85abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> The (R)-enantiomer binds with lower affinity to the orthosteric site and may functionally antagonize the (S)-enantiomer&#x27;s effects both in vitro and in vivo, potentially by interfering with allosteric modulation or SERT trafficking, which explains why the purified (S)-enantiomer exhibits superior efficacy and tolerability in clinical studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> This enantioselective pharmacology underscores the contribution of stereochemistry to citalopram&#x27;s overall mechanism, with the racemic formulation&#x27;s mixed effects possibly limiting its potency compared to escitalopram.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup></span>
<h3 id="pharmacokinetics-and-metabolism" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetics and Metabolism<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">
Citalopram is rapidly absorbed following oral administration, with peak plasma concentrations achieved 1 to 4 hours after dosing and an absolute bioavailability of approximately 80%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_66abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> The pharmacokinetics exhibit linearity and dose proportionality across the 10 to 60 mg daily range, with steady-state concentrations attained within one week of once-daily dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram distributes widely throughout the body, with a volume of distribution of about 12 L/kg, indicating extensive extravascular tissue binding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> Plasma protein binding is approximately 80%, primarily to alpha-1-acid glycoprotein.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup> The drug crosses the blood-brain barrier and is present in breast milk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Metabolism occurs predominantly in the liver via N-demethylation, yielding the primary metabolite N-desmethylcitalopram (DCIT), which possesses about one-third the serotonin reuptake inhibitory activity of the parent compound.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> This process is mediated mainly by CYP2C19 and CYP3A4, with minor contributions from CYP2D6; further demethylation produces didesmethylcitalopram (DDCIT).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Citalopram exists as a racemic mixture of R- and S-enantiomers, with the S-enantiomer responsible for most therapeutic effects and undergoing slower metabolism than the R-form.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Elimination follows a mean terminal half-life of 35 hours (range 24 to 48 hours), with 12 to 23% excreted unchanged in urine and about 10% in feces; the balance is eliminated as metabolites.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_67qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> In elderly patients, single-dose AUC and half-life increase by 30% and 50%, respectively, necessitating cautious dosing adjustments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Hepatic impairment prolongs half-life, while pharmacokinetics remain largely unaltered in renal impairment or mild to moderate hepatic disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h2 id="clinical-efficacy-and-evidence" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Efficacy and Evidence<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="evidence-for-major-depressive-disorder" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Evidence for Major Depressive Disorder<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram hydrobromide received U.S. Food and Drug Administration (FDA) approval on July 17, 1998, for the treatment of major depressive disorder (MDD) in adults, predicated on efficacy demonstrated in placebo-controlled clinical trials of 4 to 6 weeks&#x27; duration involving outpatients meeting DSM-III or DSM-III-R criteria for MDD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In one pivotal 6-week fixed-dose study (Study 1), citalopram at 40 mg/day and 60 mg/day produced statistically significant reductions in Hamilton Depression Rating Scale (HAM-D) total scores compared to placebo, whereas 10 mg/day and 20 mg/day doses did not show clear separation from placebo; the 60 mg dose offered no additional benefit over 40 mg.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> A second key 4-week trial (Study 2) employed flexible dosing starting at 20 mg/day up to a maximum of 80 mg/day, yielding significant HAM-D improvements over placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A multicenter, placebo-controlled, fixed-dose trial in 650 outpatients with moderate-to-severe MDD further supported efficacy, particularly at 40 mg/day and 60 mg/day, which outperformed placebo on HAM-D, Montgomery-Ã…sberg Depression Rating Scale (MADRS), and Clinical Global Impressions (CGI) scales, including core symptoms such as depressed mood, melancholia, cognitive disturbances, and psychomotor retardation; lower doses (10 mg and 20 mg) showed consistent but less robust advantages, significant on select MADRS and HAM-D subscales.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> Three additional placebo-controlled trials referenced in the FDA approval dossier did not demonstrate statistically significant differences versus placebo, highlighting variability across studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A 2011 systematic review and meta-analysis of five published placebo-controlled trials (total n=1,010 for response; n=1,541 for symptom reduction) found citalopram significantly superior to placebo, with a relative risk of response of 1.42 (95% CI 1.17-1.73) and a Hedges&#x27; g effect size of -0.27 (95% CI -0.38 to -0.16) for symptom reduction on continuous scales, indicating modest but reliable benefits without significant heterogeneity (IÂ²=0% for symptoms; 50.9% for response). Remission data from two trials were inconclusive, with one showing benefit (RR=1.59, 95% CI 1.10-2.31). The analysis noted poor methodological reporting in included studies, all but one industry-sponsored, raising potential bias concerns, though results aligned with broader evidence.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In a 2018 network meta-analysis of 522 trials encompassing 116,477 adults with MDD, citalopram ranked among 21 antidepressants more efficacious than placebo on acute-phase response (odds ratio 1.52, 95% CI 1.30-1.78) and remission, with standardized mean differences indicating symptom reductions, albeit with smaller inter-drug differences and tolerability trade-offs.32802-7/fulltext) Long-term placebo-controlled maintenance trials (6 months) in responders to acute citalopram (fixed 20-40 mg or flexible 20-60 mg) demonstrated delayed relapse compared to placebo switch, supporting prophylactic utility.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Efficacy appears dose-dependent, optimal at 20-40 mg/day for most patients, with current FDA guidance capping at 40 mg due to QT prolongation risks at higher doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h3 id="evidence-for-anxiety-disorders-and-other-conditions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Evidence for Anxiety Disorders and Other Conditions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram demonstrates modest efficacy in certain anxiety disorders, primarily supported by small-scale randomized controlled trials (RCTs) and open-label studies rather than large-scale meta-analyses confirming broad superiority over placebo. In generalized anxiety disorder (GAD), a double-blind RCT involving 36 elderly patients with late-life anxiety (mean age 76 years) found citalopram (20-40 mg/day) significantly reduced Hamilton Anxiety Rating Scale scores by 12.4 points compared to placebo&#x27;s 7.7 points after 12 weeks, with 68% of citalopram-treated patients achieving response (â‰¥50% symptom reduction) versus 36% on placebo. However, this trial was limited by its small sample size and focus on older adults, and broader reviews note a paucity of large RCTs establishing citalopram&#x27;s monotherapy efficacy for GAD in general populations. An open-label study of 20 GAD patients reported response rates of 85% with citalopram (up to 40 mg/day) over 8 weeks, including benefits in patients refractory to prior SSRIs, but lacked placebo control and randomization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For social anxiety disorder, an 8-week open-label trial of citalopram (20-40 mg/day) in 21 patients with or without comorbid depression yielded significant reductions in Liebowitz Social Anxiety Scale scores (from 78 to 45), with 72% classified as responders, suggesting potential utility for both generalized and performance subtypes. A meta-analysis of pharmacological treatments for anxiety disorders indicated that citalopram did not significantly outperform controls in direct comparisons, unlike other SSRIs such as sertraline or escitalopram, highlighting inconsistent effect sizes across studies. Evidence for panic disorder remains anecdotal or extrapolated from SSRI class effects, with no dedicated large RCTs identified.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond core anxiety disorders, citalopram shows preliminary support for obsessive-compulsive disorder (OCD) as an off-label application, with level 1 evidence from RCTs affirming SSRI efficacy, including citalopram doses of 40-60 mg/day yielding Yale-Brown Obsessive Compulsive Scale reductions comparable to other agents like fluoxetine, though higher doses may enhance response in refractory cases without proportional safety risks. In posttraumatic stress disorder (PTSD), evidence is weak and insufficient for recommendation; guidelines cite inadequate placebo-controlled data for citalopram, with only modest symptom improvements in small cohorts and no FDA endorsement. Limited investigations also explore citalopram for premenstrual dysphoric disorder and substance-use-related anxiety, but these lack robust RCTs and are not standard indications. Overall, while citalopram&#x27;s serotonin reuptake inhibition provides a mechanistic rationale for anxiolytic effects, its evidence base for non-depressive conditions is narrower than for escitalopram, with calls for larger trials to clarify comparative benefits and risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_acqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<h3 id="comparative-effectiveness-limitations-and-critiques" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Comparative Effectiveness, Limitations, and Critiques<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In meta-analyses of antidepressants for major depressive disorder, citalopram demonstrates efficacy superior to placebo, with response rates approximately 50-60% versus 30-40% for placebo, though effect sizes are modest (standardized mean difference around 0.3).32802-7/fulltext) <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Comparisons with other selective serotonin reuptake inhibitors (SSRIs) reveal minimal differences; for instance, citalopram shows similar improvements in Hamilton Depression Rating Scale scores to sertraline in randomized trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> However, escitalopram, the S-enantiomer of citalopram, consistently outperforms the racemic mixture in achieving acute response (odds ratio 1.47, 95% CI 1.08-2.00) and remission, with meta-analyses estimating a mean treatment difference of 1.7 points on the Montgomery-Ã…sberg Depression Rating Scale at week 8.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> This superiority is attributed to the R-enantiomer in citalopram potentially antagonizing serotonergic effects, though direct head-to-head trials in severe depression confirm escitalopram&#x27;s edge without proportional increases in adverse events.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Limitations include dose restrictions due to QT interval prolongation, a dose-dependent risk prompting FDA warnings in 2011 to cap daily doses at 40 mg overall and 20 mg for patients over 60 or with hepatic impairment, as higher doses confer arrhythmogenic potential without added efficacy benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> These caps may undermine effectiveness in non-responders requiring supratherapeutic levels, with electrocardiographic monitoring recommended for at-risk individuals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Citalopram also lacks efficacy for certain off-indication uses, such as reducing repetitive behaviors in autism spectrum disorders, where placebo-controlled trials showed no significant benefit over placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_geabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Critiques highlight the low to very low quality of evidence in many comparative studies per GRADE criteria, stemming from publication bias, heterogeneity in trial designs, and short-term endpoints that overlook long-term outcomes like relapse or functional recovery.32802-7/fulltext) The racemic formulation&#x27;s inclusion of the less active R-enantiomer is seen as inefficient compared to enantiopure alternatives like escitalopram, potentially justifying preferences for the latter in guidelines despite similar tolerability profiles.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup> Broader SSRI critiques, applicable to citalopram, question overestimation of benefits relative to harms in real-world settings, where placebo responses and natural remission rates (up to 30-50% within months) inflate perceived advantages, though citalopram-specific data align with class-wide modest number-needed-to-treat values of 7-10 for response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup></span>
<h2 id="clinical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Clinical Uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="approved-indications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Approved Indications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram, sold under the brand name Celexa among others, received initial U.S. Food and Drug Administration (FDA) approval on July 17, 1998, for the treatment of major depressive disorder (MDD) in adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> This indication is supported by clinical trials demonstrating efficacy in reducing depressive symptoms, as measured by standardized scales such as the Hamilton Depression Rating Scale.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The FDA has not approved citalopram for pediatric use, bipolar depression, or any other psychiatric conditions, reflecting limitations in trial data for these populations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_egabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the European Union, citalopram is authorized by the European Medicines Agency (EMA) for the treatment of depressive illness in adults, with marketing authorizations granted to various national agencies following centralized assessments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> This approval aligns with the FDA&#x27;s focus on MDD but excludes extensions to anxiety disorders or other off-label applications without additional evidence. Regulatory bodies emphasize that approvals are based on randomized controlled trials showing statistically significant improvements over placebo in adult MDD cohorts, typically over 6-8 weeks of treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Variations exist in other jurisdictions; for instance, some countries approve it for panic disorder, but these are not universally endorsed by major agencies like the FDA or EMA.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h3 id="off-label-applications" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Off-Label Applications<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram is employed off-label for various anxiety disorders, including panic disorder and obsessive-compulsive disorder (OCD), where selective serotonin reuptake inhibitors (SSRIs) as a class demonstrate efficacy comparable to approved agents, though specific randomized controlled trials (RCTs) for citalopram are limited. In panic disorder, open-label and small-scale studies report response rates of 60-70% after 8-12 weeks at doses of 20-40 mg/day, with reductions in panic frequency and anticipatory anxiety, but larger RCTs are needed to confirm superiority over placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> For OCD, evidence from meta-analyses of SSRIs supports moderate symptom reduction (Yale-Brown Obsessive Compulsive Scale improvements of 25-35%), with citalopram showing similar outcomes to fluoxetine or sertraline in comparative trials, often requiring doses up to 40-60 mg/day for adequate response; however, FDA approval for OCD is absent, and augmentation with antipsychotics may be necessary for refractory cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Post-traumatic stress disorder (PTSD) represents another psychiatric off-label application, inferred from citalopram&#x27;s efficacy in comorbid depression and anxiety; small RCTs indicate modest improvements in hyperarousal and intrusion symptoms (e.g., 20-30% reduction on Clinician-Administered PTSD Scale), but evidence is weaker than for sertraline or paroxetine, with no large-scale endorsement in guidelines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Beyond anxiety spectrum conditions, citalopram is used for premenstrual dysphoric disorder (PMDD), where intermittent dosing (e.g., 20 mg/day during luteal phase) yields response rates of 50-60% in RCTs, outperforming placebo in mood and irritability metrics, aligning with SSRI class benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aiabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Non-psychiatric off-label uses include postmenopausal hot flashes, with RCTs demonstrating 40-50% reduction in frequency and severity at 10-20 mg/day versus placebo, attributed to serotonergic modulation of thermoregulation, though long-term data are sparse and estrogen therapy remains first-line.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> For alcohol use disorder, adjunctive citalopram (20-40 mg/day) in RCTs reduces craving and relapse rates by 20-30% in early abstinence, particularly in patients with comorbid depression, but standalone efficacy is inconsistent without psychotherapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> In coronary artery disease patients, low-dose citalopram (10-20 mg/day) mitigates post-myocardial infarction depression and improves cardiac outcomes in secondary prevention trials, such as the SADHART-CHF study analog, by lowering inflammatory markers and enhancing adherence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Overall, while these applications leverage citalopram&#x27;s favorable tolerability profile, evidence levels vary from moderate (e.g., PMDD, hot flashes) to preliminary, with risks of QT prolongation necessitating ECG monitoring at higher doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<h2 id="administration-and-dosage" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Administration and Dosage<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="dosing-guidelines" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Dosing Guidelines<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram is administered orally as tablets or oral solution, typically once daily with or without food, in the morning or evening.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> For adults with major depressive disorder, the initial recommended dose is 20 mg once daily, with potential increase to 40 mg once daily after at least one week if clinical response is inadequate.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup> Doses exceeding 40 mg per day are not recommended due to increased risk of dose-dependent QT interval prolongation, which can lead to torsades de pointes and sudden death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In patients over 60 years of age, the maximum recommended dose is 20 mg per day, starting at 20 mg once daily, to mitigate QT prolongation risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> For individuals with hepatic impairment, the maximum dose is also limited to 20 mg per day, often starting at a lower dose such as 10-20 mg to account for reduced metabolism.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ckqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> No dosage adjustment is required for mild to moderate renal impairment, but caution is advised in severe cases with monitoring for accumulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kkqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The following table summarizes dosing recommendations by population:</span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Population</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Initial Dose</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Titration/Maintenance Dose</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Maximum Dose</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Adults (18-60 years)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20 mg once daily</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Increase to 40 mg after â‰¥1 week if needed</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">40 mg/day</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Elderly (&gt;60 years)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20 mg once daily</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">No increase beyond initial</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20 mg/day</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Hepatic impairment</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10-20 mg once daily</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Up to 20 mg</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20 mg/day</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mild-moderate renal impairment</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20 mg once daily</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">As for adults</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">40 mg/day</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Dosing should be individualized based on response and tolerability, with gradual titration to minimize adverse effects; discontinuation involves tapering to prevent withdrawal symptoms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup> CYP2C19 poor metabolizers may require dose reduction to 20 mg maximum due to elevated plasma levels and QT risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Baseline ECG is recommended for patients with cardiac risk factors before initiating higher doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gmabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h3 id="formulation-and-pharmacotherapeutic-considerations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Formulation and Pharmacotherapeutic Considerations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram hydrobromide is commercially available in immediate-release oral formulations, including film-coated tablets in strengths of 10 mg, 20 mg, and 40 mg, and an oral solution at a concentration of 10 mg per 5 mL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup> These dosage forms are designed for once-daily administration, with bioavailability of approximately 80 percent and absorption unaffected by food intake.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> The tablet and oral solution are bioequivalent, facilitating interchangeable use for dose titration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gnabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_inabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Pharmacotherapeutic considerations emphasize dose limitations to mitigate risks associated with the drug&#x27;s racemic composition, where the S-enantiomer drives selective serotonin reuptake inhibition while both enantiomers contribute to cardiac effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> The maximum recommended dose is 40 mg daily for most adults, reduced to 20 mg in patients over 60 years, those with hepatic impairment, or CYP2C19 poor metabolizers due to prolonged QT interval at higher exposures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_anqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Concomitant CYP2C19 inhibitors like cimetidine necessitate dose adjustments to avoid accumulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_enqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> The oral solution offers advantages for patients with swallowing difficulties or requiring precise low-dose adjustments, though some non-U.S. drop formulations may exhibit up to 25 percent higher bioavailability, requiring dose equivalence verification.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_inqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_knqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> Formulation selection should prioritize patient adherence and minimize excipient-related issues, such as alcohol content in certain solutions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_onqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup></span>
<h2 id="safety-profile" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Safety Profile<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="common-adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Common Adverse Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The most frequently reported adverse effects of citalopram in placebo-controlled clinical trials, defined as those occurring in at least 5% of patients and at least twice the rate observed with placebo, are primarily gastrointestinal, central nervous system, and autonomic in nature. These effects were derived from pooled data involving 1,063 citalopram-treated patients compared to 446 on placebo, across trials up to 6 weeks in duration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Incidence rates vary by dose, with higher doses associated with increased severity for effects such as somnolence and sexual dysfunction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>






































































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Adverse Effect</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Incidence in Citalopram Patients (%)</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Incidence in Placebo Patients (%)</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Nausea</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">21</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">14</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dry mouth</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">20</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">14</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Somnolence</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">18</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">10</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Insomnia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">15</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">14</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Increased sweating</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">11</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Tremor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">8</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Diarrhea</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">8</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Ejaculation disorder (males)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">6</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">1</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Dyspepsia</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Fatigue</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Upper respiratory infection</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Rhinitis</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">5</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">3</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">These effects often resolve with continued treatment or dose adjustment, though gastrointestinal symptoms like nausea typically emerge early and may affect adherence if persistent.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Sexual side effects, such as delayed ejaculation, are particularly notable in males and dose-related, occurring in up to 6% at standard therapeutic doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Overall, adverse reactions affect up to 10% of users sufficiently to warrant discontinuation in some cases, underscoring the need for monitoring during initiation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h3 id="serious-risks-including-suicidality" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Serious Risks Including Suicidality<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram, like other selective serotonin reuptake inhibitors (SSRIs), carries a boxed warning from the U.S. Food and Drug Administration (FDA) for an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults aged up to 24 years during the initial months of treatment or dose adjustments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> This risk stems from pooled analyses of short-term placebo-controlled trials showing a doubling of suicidality rates (from 2 to 4 per 1,000 patients) in pediatric and young adult populations, though completed suicides were rare.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Citalopram is not approved for use in patients under 18 years due to this elevated risk and lack of demonstrated efficacy in pediatric depression trials.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In adults over 24 years, meta-analyses of clinical trials indicate no overall increase in suicidality with SSRIs, including citalopram, and evidence suggests a potential reduction in suicide risk among older adults (over 65 years), possibly due to alleviation of depressive symptoms outweighing activation effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> Observational studies and long-term data reinforce that SSRI initiation does not elevate completed suicide rates in adults, though monitoring for worsening depression or emergent suicidality remains essential, especially in the first weeks of therapy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_grqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Beyond suicidality, citalopram poses a dose-dependent risk of QT interval prolongation, which can lead to torsades de pointes, ventricular tachycardia, or sudden cardiac death, prompting FDA recommendations against doses exceeding 40 mg daily (or 20 mg in patients over 60, those with hepatic impairment, or CYP2C19 poor metabolizers).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> This electrocardiographic effect arises from citalopram&#x27;s inhibition of cardiac potassium channels, with post-marketing reports documenting rare but serious arrhythmias, particularly at higher doses or in predisposed individuals (e.g., those with hypokalemia, bradycardia, or concomitant QT-prolonging drugs).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_csabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Screening via ECG is advised in at-risk patients, and alternatives like escitalopram may carry lower cardiac risk.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gsabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other serious risks include severe hyponatremia (often syndrome of inappropriate antidiuretic hormone secretion), which occurs in up to 0.5-1% of users, predominantly elderly females, manifesting as confusion, seizures, or coma and necessitating discontinuation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Abnormal bleeding events, such as gastrointestinal hemorrhage, are elevated due to serotonin-mediated platelet dysfunction, with odds ratios up to 1.5-2 in meta-analyses, warranting caution in patients on anticoagulants or NSAIDs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Seizures, though uncommon (incidence ~0.3%), and acute angle-closure glaucoma in susceptible individuals represent additional contraindications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_csqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> All patients require close monitoring for these adverse events, with risk-benefit assessment individualized based on comorbidities.</span>
<h3 id="long-term-effects-and-discontinuation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Long-Term Effects and Discontinuation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term use of citalopram, typically administered at doses of 20-40 mg daily for maintenance therapy in major depressive disorder, has demonstrated efficacy in preventing depressive relapse among elderly patients and those with highly recurrent unipolar depression, with studies showing sustained remission rates over 24-28 months when continued post-acute response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup> In a randomized trial involving elderly participants, citalopram maintenance reduced recurrence risk compared to placebo, with good tolerability reported over extended periods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup> However, animal models indicate potential neurotoxic effects from prolonged exposure, including male-specific impairments in motor function, learning, and memory, alongside biochemical alterations such as reduced serotonin content and metabolite levels in brain regions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_etqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gtqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_itqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Persistent adverse effects associated with long-term selective serotonin reuptake inhibitor (SSRI) therapy, including citalopram, encompass sexual dysfunction (reported in up to 71.8% of long-term users), weight gain (65.3%), and emotional numbing, which may contribute to treatment discontinuation despite ongoing therapeutic benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup> Cardiovascular risks, such as QT interval prolongation leading to arrhythmias, are heightened at doses exceeding 40 mg daily, prompting FDA recommendations against such use, particularly in patients with predisposing factors like heart failure or congenital long QT syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Observational data link extended SSRI exposure to increased cardiovascular disease risk, potentially doubling odds in some cohorts, though causality remains debated due to confounding factors like underlying depression severity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Discontinuation of citalopram often precipitates withdrawal symptoms characteristic of SSRI discontinuation syndrome, affecting 33-56% of users per systematic reviews, with manifestations including dizziness, nausea, flu-like symptoms, sensory disturbances, and anxiety emerging within days of cessation and persisting for weeks even with tapering.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6uqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup> Severe symptoms occur in approximately 2-15% of cases, underscoring the need for gradual dose reduction over weeks to months to mitigate intensity, as abrupt stops exacerbate risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_auqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup> Relapse rates are markedly higher post-discontinuation (up to 50% within months) compared to maintenance, as evidenced in primary care trials where citalopram continuation outperformed placebo in sustaining remission.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_guqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup> Case reports specific to citalopram highlight atypical presentations like pronounced psychological distress, reinforcing the syndrome&#x27;s clinical burden beyond mere relapse.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup> Guidelines emphasize monitoring during taper, as symptoms can mimic recurrence, complicating attribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ouqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup></span>
<h2 id="drug-interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Drug Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="major-interactions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Major Interactions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including reversible MAOIs such as linezolid or intravenous methylene blue, due to the risk of serious, potentially fatal serotonin syndrome; at least 14 days should elapse between discontinuing an MAOI and initiating citalopram, and vice versa.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> Concomitant use with pimozide is also contraindicated, as citalopram inhibits pimozide metabolism via CYP2D6 and both drugs prolong the QT interval, increasing the risk of torsades de pointes and sudden death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d0abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Other serotonergic agents, such as SNRIs, TCAs, triptans, tramadol, and St. John&#x27;s wort, can potentiate serotonin effects when combined with citalopram, elevating the risk of serotonin syndrome characterized by hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes; such combinations require careful monitoring or avoidance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_70qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> Pharmacokinetic interactions arise from citalopram&#x27;s metabolism primarily via CYP2C19, with lesser roles for CYP3A4 and CYP2D6; strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole) can increase citalopram exposure by up to 2-fold, necessitating dose reduction to a maximum of 20 mg/day in poor CYP2C19 metabolizers or with potent inhibitors to mitigate QT prolongation and other adverse effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Drugs that prolong the QT interval, including class IA and III antiarrhythmics (e.g., quinidine, amiodarone), antipsychotics, and certain antibiotics (e.g., erythromycin), should be avoided or used with extreme caution alongside citalopram, as the combination heightens the risk of ventricular arrhythmias, particularly at doses exceeding 40 mg/day or in patients with predisposing factors like hypokalemia or congenital long QT syndrome.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_71abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<h3 id="serotonin-syndrome-and-related-risks" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Serotonin Syndrome and Related Risks<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram, a selective serotonin reuptake inhibitor, elevates synaptic serotonin concentrations, predisposing patients to serotonin syndromeâ€”a potentially fatal condition involving excessive serotonergic activityâ€”particularly when combined with other serotonergic medications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> This syndrome manifests as a clinical triad of altered mental status (e.g., agitation, confusion), autonomic instability (e.g., tachycardia, hyperthermia, diaphoresis), and neuromuscular excitation (e.g., tremors, hyperreflexia, clonus).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup> While therapeutic doses of citalopram monotherapy infrequently precipitate severe serotonin syndrome, the risk escalates with polypharmacy involving agents like monoamine oxidase inhibitors (MAOIs), where concurrent administration has been linked to serotonergic hyperactivity in clinical evidence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Documented cases highlight interactions amplifying this hazard: for instance, co-administration with fentanyl has been deemed a probable cause of serotonin syndrome based on the Naranjo adverse drug reaction probability scale.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> Similarly, combinations with oxycodone or tramadol have resulted in syndrome onset, often tied to elevated plasma levels of the interacting drugs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup> Overdose scenarios further compound the risk, with reports of severe serotonin syndrome following single-agent citalopram ingestion, especially in individuals with impaired metabolism due to genetic polymorphisms in cytochrome P450 enzymes like CYP2C19.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup> Isolated instances of syndrome emergence after initial low-dose citalopram (e.g., 20 mg) underscore rarity but potential vulnerability in susceptible patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Relative to other classes, SSRIs including citalopram are associated with milder serotonin syndrome manifestations compared to MAOIs or their combinations, reflecting dose-dependent toxicity rather than inherent high potency for severe outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> Management entails immediate discontinuation of serotonergic agents, supportive care, and, in severe cases, serotonin antagonists like cyproheptadine; however, no prospective trials quantify citalopram-specific incidence, relying instead on case series and pharmacovigilance data. Related risks encompass exacerbated serotonergic effects in overdose, such as seizures or coma, and cautionary avoidance of concurrent use with triptans, St. John&#x27;s wort, or linezolid to mitigate cumulative serotonin accumulation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_93qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></span>
<h2 id="use-in-special-populations" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Use in Special Populations<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="pregnancy-lactation-and-reproductive-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pregnancy, Lactation, and Reproductive Effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram, classified by the FDA as Pregnancy Category C, has demonstrated adverse effects on embryo/fetal development and postnatal outcomes in animal reproduction studies, including increased embryo/fetal lethality and skeletal abnormalities at doses approximately 8 times the maximum recommended human dose, though potential risks to humans remain uncertain due to limited controlled data.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> Human studies indicate no substantial increase in major congenital malformations with first-trimester exposure to citalopram specifically, unlike paroxetine which carries a slight cardiac risk, but overall selective serotonin reuptake inhibitor (SSRI) use may associate with modest elevations in preterm birth (relative risk 1.43) and low birth weight.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Third-trimester exposure heightens risks of neonatal adaptation syndrome, manifesting as irritability, respiratory distress, and poor feeding in up to 30% of exposed infants, potentially linked to serotonin discontinuation effects rather than toxicity, with persistent pulmonary hypertension of the newborn (PPHN) occurring rarely (odds ratio around 2-3 for SSRIs generally).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup> Longer-term follow-up reveals possible associations with delayed motor development and elevated ADHD symptoms in exposed children, though confounding from maternal depression complicates causality attribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[93]</sup> Discontinuation during pregnancy may reduce certain neonatal hospitalization risks compared to continuation, but untreated maternal depression elevates preterm delivery and other complications, necessitating individualized risk-benefit assessment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_v5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[94]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In lactation, citalopram transfers into breast milk at low levels, typically 0.7-7.9% of the maternal weight-adjusted dose, rendering it generally compatible with breastfeeding per safety scoring systems, though monitoring for infant sedation, irritability, or weight gain issues is advised.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[95]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_75qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[96]</sup> Limited case reports document rare instances of infant drowsiness and feeding difficulties, but population studies of exposed infants show no consistent adverse neurodevelopmental effects, with alternatives like sertraline preferred for minimal milk transfer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[98]</sup> Experts recommend the lowest effective maternal dose and avoiding nursing during peak drug absorption to mitigate potential exposure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[99]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Regarding reproductive effects, citalopram may impair female fertility through mechanisms like elevated prolactin and corticosterone in animal models, leading to ovarian histopathology and infertility in rodents, but human evidence is inconsistent and often confounded by underlying depression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[100]</sup> In women, SSRI exposure associates with reduced conception probability independent of depression severity in some cohorts, potentially halving pregnancy rates, though untreated psychiatric illness similarly detrimentally affects fertility outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[101]</sup> For males, citalopram exposure links to reversible declines in sperm motility and concentration, with quality normalizing post-discontinuation, but does not appear to broadly compromise reproductive function at therapeutic doses.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[97]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[102]</sup> Overall, while animal data suggest caution, prospective human studies emphasize minimal direct impact beyond depression-related factors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[103]</sup></span>
<h3 id="pediatrics-and-adolescents" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pediatrics and Adolescents<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram is not approved by the U.S. Food and Drug Administration (FDA) for use in pediatric patients, including children and adolescents, due to insufficient evidence establishing safety and efficacy for major depressive disorder (MDD) or other indications in this population.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Clinical trials, such as the CIT-MD-18 study involving 174 participants aged 7-17 years with MDD, reported that citalopram (20-40 mg/day) led to greater reductions in depressive symptoms on the Children&#x27;s Depression Rating Scale-Revised compared to placebo over 8 weeks, with response rates of 38.6% versus 19.2%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[104]</sup> However, subsequent analyses and systematic reviews have questioned the robustness of these findings, noting small effect sizes, potential publication bias, and failure to demonstrate sustained benefits or superiority in broader meta-analyses of antidepressants for adolescent depression.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[105]</sup> For instance, a network meta-analysis of antidepressants found limited evidence supporting citalopram&#x27;s efficacy relative to other selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, which has FDA approval for pediatric MDD.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h7abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[106]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Safety concerns predominate in pediatric use, with a class-wide FDA black box warning for all antidepressants, including citalopram, highlighting an increased risk of suicidality in children, adolescents, and young adults. Pooled data from 24 pediatric trials (over 4,400 patients) across SSRIs showed a twofold higher rate of suicidal ideation or behavior (4% versus 2% with placebo) during initial treatment months, though no completed suicides occurred.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[107]</sup> In the CIT-MD-18 trial, citalopram was associated with higher rates of treatment-emergent suicidality (emergent suicidality risk ratio 2.19) and other adverse events like insomnia, asthenia, and rhinitis compared to placebo, prompting re-evaluation and non-approval.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_97qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[108]</sup> Guidelines from organizations such as the American Academy of Child and Adolescent Psychiatry (AACAP) and the GLAD-PC toolkit for primary care recommend psychotherapy as first-line for mild-to-moderate adolescent depression, reserving SSRIs like fluoxetine for moderate-to-severe cases with close monitoring; citalopram is not endorsed as a preferred agent due to equivocal efficacy data and heightened risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[109]</sup> Off-label prescribing occurs, particularly for obsessive-compulsive disorder (OCD) where preliminary data suggest possible benefits, but evidence remains weaker than for approved SSRIs like sertraline or fluoxetine.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[110]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Long-term data are scarce, with no large-scale studies confirming sustained efficacy or safety in youth. Discontinuation may exacerbate withdrawal symptoms or depressive relapse, and monitoring for activation syndromeâ€”manifesting as agitation or impulsivityâ€”is advised if used off-label.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_58abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[111]</sup> Overall, while some short-term symptom relief has been observed in select trials, the risk-benefit profile does not support routine use in pediatrics without specialist oversight, prioritizing evidence-based alternatives like cognitive-behavioral therapy combined with approved pharmacotherapies where indicated.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[112]</sup></span>
<h3 id="elderly-and-overdose-scenarios" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Elderly and Overdose Scenarios<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In elderly patients over 60 years of age, the maximum recommended dose of citalopram is 20 mg once daily due to heightened risk of dose-dependent QT interval prolongation, which can precipitate torsades de pointes, ventricular tachycardia, or sudden cardiac death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> This age-related vulnerability stems from reduced drug clearance and metabolism, exacerbating electrocardiographic changes observed at doses exceeding 20 mg.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Despite these risks, citalopram exhibits efficacy comparable to other antidepressants for geriatric depression, with studies showing response rates up to 65% at doses of 20-40 mg in patients with a mean age of 70.7 years, though higher doses may worsen cognition in those with Alzheimer&#x27;s-related agitation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[113]</sup> Additional adverse effects in this population include hyponatremia, increased fall risk from orthostasis, and potential associations with incident dementia, necessitating careful monitoring of serum sodium, electrolytes, and cognitive status.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[114]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram overdose primarily manifests as serotonin excess symptoms such as nausea, vomiting, drowsiness, tremor, and hyperreflexia, alongside cardiovascular effects including QT prolongation, bradycardia, and arrhythmias like torsades de pointes, particularly with ingestions exceeding 600 mg.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Seizures occur in up to 5-10% of cases, while coma is uncommon unless co-ingestants are involved; fatalities are rare but linked to refractory arrhythmias or aspiration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> Management emphasizes supportive care, including airway protection, intravenous fluids, and benzodiazepines for seizures or agitation; gastrointestinal decontamination with 50 g activated charcoal is advised if ingestion was within 4 hours and the patient remains alert for &gt;600 mg citalopram.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[115]</sup> Continuous ECG monitoring is mandatory for at least 24 hours in symptomatic patients or those with doses &gt;600 mg, extending to 13 hours minimum for ingestions &gt;1000 mg, with sodium bicarbonate or magnesium sulfate for QTc &gt;500 ms or torsades.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[117]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[116]</sup> Cytochrome P450 inhibition is not a primary concern in overdose, and hemodialysis is ineffective due to high protein binding and large volume of distribution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h2 id="history-and-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History and Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="discovery-and-clinical-trials" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Discovery and Clinical Trials<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram was synthesized in 1972 by chemists at the Danish pharmaceutical company H. Lundbeck A/S, initially designated as Lu 10-171, as part of efforts to develop selective serotonin reuptake inhibitors following the firm&#x27;s earlier work on antidepressants like Saroten launched in the 1960s.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[118]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> The compound&#x27;s structure, a racemic mixture of R- and S-enantiomers, was patented by Lundbeck prior to clinical evaluation, targeting enhanced serotonin reuptake inhibition with reduced affinity for other neurotransmitter systems compared to prior tricyclic antidepressants.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_bbabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[120]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinical development spanned approximately 15 years post-synthesis, with initial trials commencing in the late 1970s. An early open-label study involving depressive patients, published in 1980, reported preliminary evidence of antidepressant efficacy at doses of 20-60 mg daily, prompting calls for controlled evaluations to confirm therapeutic value and safety.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[121]</sup> Subsequent placebo-controlled and comparative trials in Europe during the 1980s demonstrated statistically significant improvements in Hamilton Depression Rating Scale scores versus placebo, with response rates around 50-60% in major depressive disorder cohorts, and a favorable side-effect profile dominated by nausea and dry mouth rather than anticholinergic effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[122]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By the late 1980s, aggregated data from multiple phase III trials supported regulatory approval in Denmark in 1989 as Cipramil for depressive illness, marking the first market introduction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[119]</sup> Further international trials, including those bridging European and U.S. protocols, confirmed efficacy in anxiety-associated depression and led to approvals in over 70 countries by the early 1990s, with U.S. Food and Drug Administration authorization in 1998 as Celexa based on randomized, double-blind studies showing superiority over placebo in reducing depressive symptoms by week 4-6.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[123]</sup> These trials typically enrolled 100-400 participants per study, emphasizing outpatient settings and short-term efficacy endpoints of 6-8 weeks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dcabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[124]</sup></span>
<h3 id="regulatory-approvals-and-patent-issues" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Regulatory Approvals and Patent Issues<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Citalopram hydrobromide was approved by the U.S. Food and Drug Administration (FDA) on July 17, 1998, for the treatment of major depressive disorder in adults, marketed as Celexa tablets by Forest Laboratories, Inc.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[125]</sup> Subsequent formulations, including an oral solution, received approval on March 27, 2012, with revisions to labeling for safety updates.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[126]</sup> In 2011, the FDA issued warnings limiting the maximum daily dose to 40 mg due to risks of QT interval prolongation and added restrictions for patients over 60 or with hepatic impairment, reducing it to 20 mg.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ddabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the European Union, citalopram has been authorized nationally since 1989, initially in Denmark as Cipramil by H. Lundbeck A/S, with subsequent approvals in other member states for depression treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[127]</sup> The European Medicines Agency (EMA) oversees post-authorization safety updates, including alignment with FDA dose restrictions following cardiac risk assessments. No centralized marketing authorization exists, as it predates the EMA&#x27;s mutual recognition procedures for many indications.</span>
<span class="mb-4 block break-words text-[1em] leading-7">The compound patent for citalopram, held by Lundbeck, expired in 2003, enabling generic entry in the U.S. market by late 2004 after resolution of litigation challenges.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[128]</sup> Forest Laboratories faced Paragraph IV patent certifications from generic manufacturers, leading to suits under the Hatch-Waxman Act to defend exclusivity, with generics like those from Teva approved shortly after. In Europe, Lundbeck entered settlement agreements with generic firms (e.g., Ranbaxy, Barr) between 1999 and 2002, paying them to delay market entry despite the expiring compound patent, relying instead on secondary process patents of limited scope.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These settlements prompted antitrust scrutiny; in 2013, the European Commission fined Lundbeck â‚¬93.8 million and generics â‚¬52.2 million total for restricting competition, classifying the deals as &quot;pay-for-delay&quot; schemes that artificially extended market dominance beyond valid patent protection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[129]</sup> The Court of Justice of the EU upheld the decision in 2021, affirming that such agreements, even amid genuine patent disputes, constituted restrictions by object under EU competition law when generics were potential competitors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[130]</sup> Similar U.S. probes by the FTC examined reverse payments but did not result in penalties specific to citalopram, contrasting with Europe&#x27;s broader application to secondary patents.</span>
<h2 id="societal-and-regulatory-context" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Societal and Regulatory Context<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="prescribing-trends-and-market-dynamics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Prescribing Trends and Market Dynamics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, citalopram prescriptions reached approximately 14.8 million in 2023, reflecting sustained but declining use as a selective serotonin reuptake inhibitor (SSRI) primarily for major depressive disorder.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[131]</sup> Overall SSRI prescribing has contributed to a 109% increase in antidepressant utilization from 2010 to 2023, yet citalopram specifically exhibits a downward trajectory, with use decreasing among Medicare and Medicaid beneficiaries from 2015 to 2020.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[132]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[133]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This decline correlates with the 2011 U.S. Food and Drug Administration (FDA) warning limiting maximum daily doses to 40 mg due to dose-dependent QT interval prolongation risks, revised in 2012 to 20 mg for patients over 60 years old.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Studies confirm reduced high-dose prescribing post-warning, with regulatory changes achieving notable decreases in supratherapeutic use, though approximately one-third of older adults remained on higher doses in some cohorts, alongside unintended increases in anxiolytic and sedative co-prescribing and healthcare utilization.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[134]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[135]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hgqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[136]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Concurrent shifts favor escitalopram, the S-enantiomer of citalopram approved in 2002, which has seen rising prescription rates in parallel databases, potentially driven by marketing strategies, perceived superior efficacy in meta-analyses (e.g., 1.7-point MADRS score advantage), and lower doses for equivalent effects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> Citalopram&#x27;s racemic structure, including the less active R-enantiomer, may contribute to this preference amid evidence of escitalopram&#x27;s better tolerability profile.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Market dynamics shifted markedly after generic entry in October 2004, following Celexa (branded citalopram) approval in 1998, eroding brand-name revenues through saturation and competition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[138]</sup> Global citalopram revenues, largely from generics, peaked at an estimated $1.2 billion in 2016 before stabilizing amid broader SSRI options.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[139]</sup> Generic pricing advantages persist, with citalopram remaining cost-competitive against escitalopram, though evergreening tacticsâ€”such as escitalopram&#x27;s promotion as an optimized formulationâ€”have influenced prescriber behavior and market share allocation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_dhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[137]</sup> Projections indicate modest compound growth to $1.8 billion by 2033, tempered by prescription declines and regulatory scrutiny.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hhqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[140]</sup></span>
<h3 id="controversies-including-overprescription-and-public-health-debates" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Controversies Including Overprescription and Public Health Debates<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In 2011, the U.S. Food and Drug Administration (FDA) issued a safety communication warning that citalopram causes dose-dependent QT interval prolongation, increasing the risk of potentially fatal abnormal heart rhythms such as torsades de pointes, and advised against prescribing doses exceeding 40 mg per day overall or 20 mg per day in patients over 60 years old or with hepatic impairment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> This followed post-marketing reports and electrocardiographic data indicating a mean QTc increase of 8.5 ms at 20 mg, 18.5 ms at 40 mg, and 20.3 ms at 60 mg, with recommendations to avoid use in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, or recent myocardial infarction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> The warning was revised in 2012 and further in 2017, softening contraindications to &quot;not recommended&quot; for higher doses while emphasizing ECG monitoring and risk factor avoidance, amid concerns that abrupt changes could disrupt treatment for millions of users.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_diqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Subsequent research has sparked debate over the warning&#x27;s clinical significance and potential for overcaution. A 2013 observational study of over 38,000 patients found no elevated risks of ventricular arrhythmia or all-cause mortality with citalopram doses above 40 mg per day compared to other antidepressants, even after adjusting for confounders like age and comorbidities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[141]</sup> Similarly, a literature review identified no cases of citalopram-induced sudden cardiac death in patients taking up to 60 mg daily without additional risk factors, questioning the threshold&#x27;s basis in real-world arrhythmia incidence rather than surrogate QTc changes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[142]</sup> Critics, including some psychiatrists, argue the FDA&#x27;s emphasis on ECG abnormalities may exaggerate population-level risks, given citalopram&#x27;s perceived efficacy at higher doses for treatment-resistant depression, with one analysis estimating 12% of prescriptions exceeded 40 mg pre-warning due to clinical judgment of benefits outweighing theoretical harms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_djabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[143]</sup> Health Canada issued a parallel advisory in 2012, correlating with reduced prescribing of citalopram and escitalopram (from 44.1% to 22.3% of relevant cases), though without corresponding improvements in dose safety.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[144]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Overprescription concerns for citalopram tie into broader antidepressant trends, amplified by its low cost as a generic since 2004 and widespread off-label use for anxiety, insomnia, and pain beyond major depressive disorder. In 2011, U.S. outpatient pharmacies dispensed citalopram to approximately 7.2 million patients, reflecting high-volume utilization amid rising SSRI prescriptions overall.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Post-FDA warning, prescribing patterns shifted toward more ECG monitoring (from negligible to significant increases), but high-dose usage persisted in subsets, with no substantial drop in doses above 20 mg, suggesting incomplete adherence or perceived necessity despite guidelines.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[145]</sup> Public health advocates have highlighted risks of unnecessary exposure in mild cases, where SSRIs like citalopram show marginal benefits over placebo in meta-analyses, potentially medicalizing normal distress while incurring side effects such as bleeding risks from serotonin-mediated platelet inhibition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_djqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">These issues fuel ongoing debates about regulatory warnings&#x27; balance between precaution and evidence-based practice. While FDA actions aimed to mitigate rare but serious cardiac events in a large exposed population, empirical data from large cohorts indicate low absolute arrhythmia rates even at higher doses, prompting calls for personalized risk assessment over blanket limits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[146]</sup> In vulnerable groups, such as the elderly, the warnings underscore public health priorities of minimizing polypharmacy interactions and iatrogenic harm, yet they may inadvertently reduce access to effective therapy for severe depression, where citalopram&#x27;s role remains substantiated by measurement-based care studies showing response rates up to 50-60% in routine practice.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_9kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[147]</sup> Overall, the controversies highlight tensions between pharmacovigilance signals and causal attribution challenges in observational data, with no consensus on whether warnings have optimized net patient safety.</span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK482222/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK482222/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK482222/</a></span></div></li><li id="https://go.drugbank.com/drugs/DB00215" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://go.drugbank.com/drugs/DB00215" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://go.drugbank.com/drugs/DB00215</a></span></div></li><li id="https://jamanetwork.com/journals/jama/fullarticle/205268" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jama/fullarticle/205268" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jama/fullarticle/205268</a></span></div></li><li id="https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/efficacy-of-citalopram-in-the-prevention-of-recurrent-depression-in-elderly-patients-placebocontrolled-study-of-maintenance-therapy/9B8AD15F5345ADE1BFD6DEE7BEA9D187" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/efficacy-of-citalopram-in-the-prevention-of-recurrent-depression-in-elderly-patients-placebocontrolled-study-of-maintenance-therapy/9B8AD15F5345ADE1BFD6DEE7BEA9D187" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/efficacy-of-citalopram-in-the-prevention-of-recurrent-depression-in-elderly-patients-placebocontrolled-study-of-maintenance-therapy/9B8AD15F5345ADE1BFD6DEE7BEA9D187</a></span></div></li><li id="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram</a></span></div></li><li id="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related</a></span></div></li><li id="https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram</a></span></div></li><li id="https://precision.fda.gov/ginas/app/ui/substances/87ac0121-f698-4b47-b330-7a60e77925f3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://precision.fda.gov/ginas/app/ui/substances/87ac0121-f698-4b47-b330-7a60e77925f3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://precision.fda.gov/ginas/app/ui/substances/87ac0121-f698-4b47-b330-7a60e77925f3</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC353039/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC353039/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC353039/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC1574928/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1574928/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC1574928/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10321182/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10321182/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10321182/</a></span></div></li><li id="https://www.clinpgx.org/pathway/PA164713429" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.clinpgx.org/pathway/PA164713429" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.clinpgx.org/pathway/PA164713429</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf</a></span></div></li><li id="https://www.nature.com/articles/s41467-020-15292-y" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41467-020-15292-y" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41467-020-15292-y</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/27665061/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/27665061/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/27665061/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/15695064/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/15695064/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/15695064/</a></span></div></li><li id="https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0705738" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0705738" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0705738</a></span></div></li><li id="https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2006.pto_295.x" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2006.pto_295.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2006.pto_295.x</a></span></div></li><li id="https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/</a></span></div></li><li id="https://www.researchgate.net/figure/The-two-enantiomers-of-citalopram-Citalopram-is-a-racemate_fig1_8546695" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/figure/The-two-enantiomers-of-citalopram-Citalopram-is-a-racemate_fig1_8546695" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/figure/The-two-enantiomers-of-citalopram-Citalopram-is-a-racemate_fig1_8546695</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10665628/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10665628/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10665628/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/15625213/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/15625213/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/15625213/</a></span></div></li><li id="https://psychiatryonline.org/doi/full/10.1176/appi.ajp.162.1.146" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/full/10.1176/appi.ajp.162.1.146" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/full/10.1176/appi.ajp.162.1.146</a></span></div></li><li id="https://www.psychiatrist.com/jcp/pharmacologic-treatment-anxiety-disorders-review-progress/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatrist.com/jcp/pharmacologic-treatment-anxiety-disorders-review-progress/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatrist.com/jcp/pharmacologic-treatment-anxiety-disorders-review-progress/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/11981350/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/11981350/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/11981350/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0278584601002366" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0278584601002366" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0278584601002366</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/25932596/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/25932596/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/25932596/</a></span></div></li><li id="https://www.camh.ca/en/professionals/treating-conditions-and-disorders/ocd/ocd---treatment/ocd---pharmacotherapy" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.camh.ca/en/professionals/treating-conditions-and-disorders/ocd/ocd---treatment/ocd---pharmacotherapy" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.camh.ca/en/professionals/treating-conditions-and-disorders/ocd/ocd---treatment/ocd---pharmacotherapy</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0010440X24000373" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0010440X24000373" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0010440X24000373</a></span></div></li><li id="https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp</a></span></div></li><li id="https://psychiatryonline.org/doi/10.1176/appi.focus.20200048" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/10.1176/appi.focus.20200048" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/10.1176/appi.focus.20200048</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/29477251/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/29477251/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/29477251/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0006322300009574" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0006322300009574" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0006322300009574</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4204633/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4204633/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4204633/</a></span></div></li><li id="https://academic.oup.com/ijnp/article/14/2/261/696727" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://academic.oup.com/ijnp/article/14/2/261/696727" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://academic.oup.com/ijnp/article/14/2/261/696727</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/15107719/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/15107719/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/15107719/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6007721/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6007721/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6007721/</a></span></div></li><li id="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/210271" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/210271" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamapsychiatry/fullarticle/210271</a></span></div></li><li id="https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05382-8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05382-8" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05382-8</a></span></div></li><li id="https://www.acpjournals.org/doi/10.7326/0003-4819-155-11-201112060-00009" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.acpjournals.org/doi/10.7326/0003-4819-155-11-201112060-00009" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.acpjournals.org/doi/10.7326/0003-4819-155-11-201112060-00009</a></span></div></li><li id="https://www.ema.europa.eu/en/medicines" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/medicines" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ema.europa.eu/en/medicines</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9645290/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9645290/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9645290/</a></span></div></li><li id="https://www.aafp.org/pubs/afp/issues/2003/0801/p498.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.aafp.org/pubs/afp/issues/2003/0801/p498.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.aafp.org/pubs/afp/issues/2003/0801/p498.html</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC9878961/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9878961/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC9878961/</a></span></div></li><li id="https://www.drugs.com/dosage/citalopram.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/dosage/citalopram.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/dosage/citalopram.html</a></span></div></li><li id="https://reference.medscape.com/drug/celexa-citalopram-342958" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://reference.medscape.com/drug/celexa-citalopram-342958" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://reference.medscape.com/drug/celexa-citalopram-342958</a></span></div></li><li id="https://www.mayoclinic.org/drugs-supplements/citalopram-oral-route/description/drg-20062980" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/drugs-supplements/citalopram-oral-route/description/drg-20062980" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/drugs-supplements/citalopram-oral-route/description/drg-20062980</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037%2C021046s015lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037%2C021046s015lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037%2C021046s015lbl.pdf</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf</a></span></div></li><li id="https://www.medicines.org.uk/emc/product/3349/smpc" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medicines.org.uk/emc/product/3349/smpc" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medicines.org.uk/emc/product/3349/smpc</a></span></div></li><li id="https://www.hpft.nhs.uk/media/1942/19-citalopram-tabs-or-drops-equivalent-doses-march-2012.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hpft.nhs.uk/media/1942/19-citalopram-tabs-or-drops-equivalent-doses-march-2012.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hpft.nhs.uk/media/1942/19-citalopram-tabs-or-drops-equivalent-doses-march-2012.pdf</a></span></div></li><li id="https://www.nature.com/articles/s41386-021-01179-z" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41386-021-01179-z" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41386-021-01179-z</a></span></div></li><li id="https://www.bmj.com/content/339/bmj.b2880" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bmj.com/content/339/bmj.b2880" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bmj.com/content/339/bmj.b2880</a></span></div></li><li id="https://journals.lww.com/ebp/fulltext/2009/10000/does_the_initiation_of_an_ssri_for_depression.14.aspx" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.lww.com/ebp/fulltext/2009/10000/does_the_initiation_of_an_ssri_for_depression.14.aspx" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.lww.com/ebp/fulltext/2009/10000/does_the_initiation_of_an_ssri_for_depression.14.aspx</a></span></div></li><li id="https://www.medrxiv.org/content/10.1101/2020.05.11.20098178.full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medrxiv.org/content/10.1101/2020.05.11.20098178.full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medrxiv.org/content/10.1101/2020.05.11.20098178.full</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/12091260/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/12091260/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/12091260/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/11740983/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/11740983/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/11740983/</a></span></div></li><li id="https://mentalhealth.bmj.com/content/6/1/24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://mentalhealth.bmj.com/content/6/1/24" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://mentalhealth.bmj.com/content/6/1/24</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/35985052/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/35985052/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/35985052/</a></span></div></li><li id="https://pubs.acs.org/doi/abs/10.1021/acs.est.2c01514" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubs.acs.org/doi/abs/10.1021/acs.est.2c01514" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubs.acs.org/doi/abs/10.1021/acs.est.2c01514</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/20946930/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/20946930/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/20946930/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4970636/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4970636/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4970636/</a></span></div></li><li id="https://www.bristol.ac.uk/primaryhealthcare/news/2022/adverse-health-outcomes-associated-with-long-term-antidepressant-use.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bristol.ac.uk/primaryhealthcare/news/2022/adverse-health-outcomes-associated-with-long-term-antidepressant-use.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bristol.ac.uk/primaryhealthcare/news/2022/adverse-health-outcomes-associated-with-long-term-antidepressant-use.html</a></span></div></li><li id="https://www.psychiatryonline.org/doi/10.1176/appi.pn.2025.09.9.1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatryonline.org/doi/10.1176/appi.pn.2025.09.9.1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatryonline.org/doi/10.1176/appi.pn.2025.09.9.1</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/25721705/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/25721705/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/25721705/</a></span></div></li><li id="https://www.jwatch.org/na57759/2024/07/30/antidepressant-discontinuation-syndrome-meta-analysis" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jwatch.org/na57759/2024/07/30/antidepressant-discontinuation-syndrome-meta-analysis" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jwatch.org/na57759/2024/07/30/antidepressant-discontinuation-syndrome-meta-analysis</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4722507/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4722507/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4722507/</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2106356" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2106356" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2106356</a></span></div></li><li id="https://www.pulsus.com/scholarly-articles/an-interesting-discontinuation-syndrome-with-citalopram-a-case-report.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pulsus.com/scholarly-articles/an-interesting-discontinuation-syndrome-with-citalopram-a-case-report.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pulsus.com/scholarly-articles/an-interesting-discontinuation-syndrome-with-citalopram-a-case-report.pdf</a></span></div></li><li id="https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2824%2900133-0/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2824%2900133-0/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2824%2900133-0/fulltext</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020822s29lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020822s29lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020822s29lbl.pdf</a></span></div></li><li id="https://assets.hpra.ie/products/Human/24269/LicenseSPC_PA1063-017-001_28052013171216.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://assets.hpra.ie/products/Human/24269/LicenseSPC_PA1063-017-001_28052013171216.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://assets.hpra.ie/products/Human/24269/LicenseSPC_PA1063-017-001_28052013171216.pdf</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK482377/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK482377/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK482377/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3865832/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3865832/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3865832/</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/17381671/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/17381671/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/17381671/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3368298/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3368298/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3368298/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4276375/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4276375/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4276375/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0735675719304176" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0735675719304176" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0735675719304176</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0161813X0700085X" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0161813X0700085X" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0161813X0700085X</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6184959/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6184959/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6184959/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4469720/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4469720/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4469720/</a></span></div></li><li id="https://www.uspharmacist.com/article/drug-induced-serotonin-syndrome" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.uspharmacist.com/article/drug-induced-serotonin-syndrome" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.uspharmacist.com/article/drug-induced-serotonin-syndrome</a></span></div></li><li id="https://www.drugs.com/pregnancy/citalopram.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/pregnancy/citalopram.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/pregnancy/citalopram.html</a></span></div></li><li id="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2769190" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2769190" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2769190</a></span></div></li><li id="https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/antidepressants/art-20046420" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/antidepressants/art-20046420" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/antidepressants/art-20046420</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10590209/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10590209/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10590209/</a></span></div></li><li id="https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1193-5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1193-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1193-5</a></span></div></li><li id="https://www.ajog.org/article/S0002-9378%2818%2930709-9/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ajog.org/article/S0002-9378%2818%2930709-9/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ajog.org/article/S0002-9378%2818%2930709-9/fulltext</a></span></div></li><li id="https://publications.aap.org/pediatrics/article/142/1/e20180356/37500/Prenatal-Antidepressant-Exposure-and-Child-Motor" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://publications.aap.org/pediatrics/article/142/1/e20180356/37500/Prenatal-Antidepressant-Exposure-and-Child-Motor" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://publications.aap.org/pediatrics/article/142/1/e20180356/37500/Prenatal-Antidepressant-Exposure-and-Child-Motor</a></span></div></li><li id="https://www.nature.com/articles/s41398-023-02441-2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nature.com/articles/s41398-023-02441-2" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nature.com/articles/s41398-023-02441-2</a></span></div></li><li id="https://www.sciencedirect.com/science/article/pii/S0165178124005596" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/pii/S0165178124005596" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/pii/S0165178124005596</a></span></div></li><li id="https://www.ncbi.nlm.nih.gov/books/NBK501185/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ncbi.nlm.nih.gov/books/NBK501185/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.ncbi.nlm.nih.gov/books/NBK501185/</a></span></div></li><li id="https://www.sps.nhs.uk/articles/using-ssri-antidepressants-during-breastfeeding/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sps.nhs.uk/articles/using-ssri-antidepressants-during-breastfeeding/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sps.nhs.uk/articles/using-ssri-antidepressants-during-breastfeeding/</a></span></div></li><li id="https://mothertobaby.org/fact-sheets/citalopramescitalopram-celexalexapro-pregnancy/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://mothertobaby.org/fact-sheets/citalopramescitalopram-celexalexapro-pregnancy/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://mothertobaby.org/fact-sheets/citalopramescitalopram-celexalexapro-pregnancy/</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1414677/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1414677/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1414677/full</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/10664835/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/10664835/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/10664835/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0890623825000309" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0890623825000309" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0890623825000309</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4965341/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4965341/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4965341/</a></span></div></li><li id="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1567863/full" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1567863/full" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1567863/full</a></span></div></li><li id="https://womensmentalhealth.org/posts/antidepressants-impact-fertility/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://womensmentalhealth.org/posts/antidepressants-impact-fertility/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://womensmentalhealth.org/posts/antidepressants-impact-fertility/</a></span></div></li><li id="https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.6.1079" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.6.1079" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.6.1079</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC3222577/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3222577/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC3222577/</a></span></div></li><li id="https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2820%2930137-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2820%2930137-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2820%2930137-1/fulltext</a></span></div></li><li id="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications</a></span></div></li><li id="https://journals.sagepub.com/doi/10.3233/JRS-160671" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://journals.sagepub.com/doi/10.3233/JRS-160671" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://journals.sagepub.com/doi/10.3233/JRS-160671</a></span></div></li><li id="https://publications.aap.org/pediatrics/article/141/3/e20174082/37654/Guidelines-for-Adolescent-Depression-in-Primary" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://publications.aap.org/pediatrics/article/141/3/e20174082/37654/Guidelines-for-Adolescent-Depression-in-Primary" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://publications.aap.org/pediatrics/article/141/3/e20174082/37654/Guidelines-for-Adolescent-Depression-in-Primary</a></span></div></li><li id="https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/citalopram/263A565EEAEAF8962B276D8763FDC922" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/citalopram/263A565EEAEAF8962B276D8763FDC922" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/citalopram/263A565EEAEAF8962B276D8763FDC922</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6738970/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6738970/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6738970/</a></span></div></li><li id="https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-224-depression-children-final-report.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-224-depression-children-final-report.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-224-depression-children-final-report.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC6607952/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6607952/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC6607952/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4760914/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4760914/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4760914/</a></span></div></li><li id="https://litfl.com/ssri-toxicity/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://litfl.com/ssri-toxicity/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://litfl.com/ssri-toxicity/</a></span></div></li><li id="https://emedicine.medscape.com/article/821737-treatment" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/821737-treatment" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/821737-treatment</a></span></div></li><li id="https://litfl.com/citalopram-overdose/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://litfl.com/citalopram-overdose/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://litfl.com/citalopram-overdose/</a></span></div></li><li id="https://www.imrpress.com/journal/AP/26/2/10.31083/AP40037/htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.imrpress.com/journal/AP/26/2/10.31083/AP40037/htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.imrpress.com/journal/AP/26/2/10.31083/AP40037/htm</a></span></div></li><li id="https://www.lundbeck.com/us/about-us/this-is-lundbeck/our-history" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lundbeck.com/us/about-us/this-is-lundbeck/our-history" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lundbeck.com/us/about-us/this-is-lundbeck/our-history</a></span></div></li><li id="https://www.chm.bris.ac.uk/motm/citalopram/citalopramh.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.chm.bris.ac.uk/motm/citalopram/citalopramh.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.chm.bris.ac.uk/motm/citalopram/citalopramh.htm</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/6935914/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/6935914/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/6935914/</a></span></div></li><li id="https://link.springer.com/article/10.1007/BF00606656" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/BF00606656" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/BF00606656</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10197723/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10197723/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10197723/</a></span></div></li><li id="https://www.sciencedirect.com/topics/chemistry/citalopram" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/topics/chemistry/citalopram" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/topics/chemistry/citalopram</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm</a></span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021046Orig1s019.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021046Orig1s019.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021046Orig1s019.pdf</a></span></div></li><li id="https://ogyei.gov.hu/kiseroirat/ph/ph_0000021931.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ogyei.gov.hu/kiseroirat/ph/ph_0000021931.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ogyei.gov.hu/kiseroirat/ph/ph_0000021931.pdf</a></span></div></li><li id="https://www.drugs.com/availability/generic-celexa.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/availability/generic-celexa.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/availability/generic-celexa.html</a></span></div></li><li id="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0307%2801%29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0307%2801%29" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0307%2801%29</a></span></div></li><li id="https://curia.europa.eu/jcms/jcms/p1_3471475/fr/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://curia.europa.eu/jcms/jcms/p1_3471475/fr/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://curia.europa.eu/jcms/jcms/p1_3471475/fr/</a></span></div></li><li id="https://www.statista.com/statistics/781811/citalopram-prescriptions-number-in-the-us/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.statista.com/statistics/781811/citalopram-prescriptions-number-in-the-us/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.statista.com/statistics/781811/citalopram-prescriptions-number-in-the-us/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC12360015/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12360015/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC12360015/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC11919847/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11919847/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC11919847/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC4468881/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4468881/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC4468881/</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S1064748117304736" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S1064748117304736" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S1064748117304736</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/28012712/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/28012712/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/28012712/</a></span></div></li><li id="https://www.researchgate.net/publication/370609774_Rise_of_escitalopram_and_the_fall_of_citalopram" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/370609774_Rise_of_escitalopram_and_the_fall_of_citalopram" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/370609774_Rise_of_escitalopram_and_the_fall_of_citalopram</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC2719790/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2719790/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC2719790/</a></span></div></li><li id="https://www.drugpatentwatch.com/p/generic-api/CITALOPRAM%2BHYDROBROMIDE" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugpatentwatch.com/p/generic-api/CITALOPRAM%2BHYDROBROMIDE" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugpatentwatch.com/p/generic-api/CITALOPRAM%2BHYDROBROMIDE</a></span></div></li><li id="https://www.verifiedmarketreports.com/product/citalopram-market/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.verifiedmarketreports.com/product/citalopram-market/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.verifiedmarketreports.com/product/citalopram-market/</a></span></div></li><li id="https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.12030408" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.12030408" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.12030408</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/22748401/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/22748401/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/22748401/</a></span></div></li><li id="https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.13081052" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.13081052" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.13081052</a></span></div></li><li id="https://www.sciencedirect.com/science/article/abs/pii/S0033318215001528" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sciencedirect.com/science/article/abs/pii/S0033318215001528" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sciencedirect.com/science/article/abs/pii/S0033318215001528</a></span></div></li><li id="https://www.psychiatrist.com/pcc/evaluation-changes-citalopram-prescribing-patterns/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.psychiatrist.com/pcc/evaluation-changes-citalopram-prescribing-patterns/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.psychiatrist.com/pcc/evaluation-changes-citalopram-prescribing-patterns/</a></span></div></li><li id="https://www.thecarlatreport.com/articles/2597-high-dose-citalopram-and-escitalopram-undeserved-bad-rap-" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.thecarlatreport.com/articles/2597-high-dose-citalopram-and-escitalopram-undeserved-bad-rap-" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.thecarlatreport.com/articles/2597-high-dose-citalopram-and-escitalopram-undeserved-bad-rap-</a></span></div></li><li id="https://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.28" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.28</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi" id="_R_" async=""></script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Citalopram\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Citalopram\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Citalopram\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T125a0,"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"# Citalopram\n\n![Citalopram chemical structure](./_assets_/Citalopram_racemic.svg.png)\nCitalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf)[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Approved in 1998, citalopram is marketed under the brand name Celexa and exists as a racemic mixture of R- and S-enantiomers, with the S-enantiomer (escitalopram) demonstrating greater potency at the serotonin transporter.[](https://go.drugbank.com/drugs/DB00215) Clinical trials have established its efficacy in alleviating depressive symptoms, outperforming placebo in reducing Hamilton Depression Rating Scale scores and preventing relapse in maintenance therapy, particularly among elderly patients.[](https://jamanetwork.com/journals/jama/fullarticle/205268)[](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/efficacy-of-citalopram-in-the-prevention-of-recurrent-depression-in-elderly-patients-placebocontrolled-study-of-maintenance-therapy/9B8AD15F5345ADE1BFD6DEE7BEA9D187) However, its use has been associated with dose-dependent QT interval prolongation, prompting FDA warnings against doses exceeding 40 mg daily due to risks of torsades de pointes and sudden cardiac death, alongside a black box warning for heightened suicidality risk in pediatric and young adult populations.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram)[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) Common adverse effects include nausea, dry mouth, somnolence, and sexual dysfunction, reflecting its serotonergic profile.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\n## Pharmacology\n\n### Chemical Structure and Stereochemistry\n\n![Citalopram racemic structure](./_assets_/Citalopram_racemic.svg.png)\n\nCitalopram has the molecular formula Câ‚‚â‚€Hâ‚‚â‚FNâ‚‚O and the IUPAC name 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile.[](https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram) Its core scaffold is a 1,3-dihydro-2-benzofuran (isobenzofuran) ring system bearing a cyano substituent at the 5-position and, at the 1-position, both a 4-fluorophenyl group and a 3-(dimethylamino)propyl side chain.[](https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram) This 1-position carbon serves as the sole stereogenic center.[](https://precision.fda.gov/ginas/app/ui/substances/87ac0121-f698-4b47-b330-7a60e77925f3)\n\nThe pharmaceutical formulation of citalopram is administered as a 1:1 racemic mixture of its (R)- and (S)-enantiomers.[](https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram) The (S)-(+)-enantiomer, escitalopram, exhibits substantially higher potency in inhibiting serotonin reuptake compared to the (R)-(-)-enantiomer, which demonstrates over 100-fold lower affinity for the serotonin transporter.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC353039/) The (R)-enantiomer exerts minimal direct serotonergic effects but can allosterically antagonize the activity of the (S)-enantiomer, potentially diminishing overall efficacy in the racemate.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC1574928/) This stereoselective pharmacology underpins the development of escitalopram as a purified enantiomer for enhanced therapeutic profile.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10321182/)\n\n### Mechanism of Action\n\nCitalopram is a selective serotonin reuptake inhibitor (SSRI) that primarily exerts its pharmacological effects by blocking the serotonin transporter (SERT, encoded by *SLC6A4*), thereby inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft into presynaptic neurons.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://www.clinpgx.org/pathway/PA164713429) This action increases extracellular serotonin concentrations in the central nervous system, potentiating serotonergic neurotransmission.[](https://go.drugbank.com/drugs/DB00215)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf) The antidepressant efficacy of citalopram is presumed to stem from this enhancement of serotonergic activity, though the precise downstream adaptations required for therapeutic effectsâ€”such as desensitization of presynaptic 5-HT\u003csub\u003e1A\u003c/sub\u003e autoreceptors and alterations in postsynaptic receptor signalingâ€”remain incompletely elucidated and occur over weeks despite rapid SERT occupancy.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://go.drugbank.com/drugs/DB00215)\n\nCitalopram demonstrates high affinity for SERT (inhibition constant *K*\u003csub\u003ei\u003c/sub\u003e approximately 1â€“10 nM for the active enantiomer), with substantially lower affinity for norepinephrine (NET) and dopamine (DAT) transporters (*K*\u003csub\u003ei\u003c/sub\u003e \u003e1,000 nM), conferring its selectivity as an SSRI over other monoamine transporters.[](https://www.clinpgx.org/pathway/PA164713429)[](https://www.nature.com/articles/s41467-020-15292-y) At therapeutic concentrations, it exhibits minimal direct interactions with serotonin receptors (e.g., 5-HT\u003csub\u003e1A\u003c/sub\u003e, 5-HT\u003csub\u003e2A\u003c/sub\u003e) or other neurotransmitter systems, though weak antagonism at histamine H\u003csub\u003e1\u003c/sub\u003e and muscarinic receptors has been noted at higher doses.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Additionally, citalopram binds to an allosteric site on SERT distinct from the orthosteric (primary substrate/inhibitor) site, which modulates inhibitor binding kinetics, reduces dissociation rates, and may contribute to its sustained inhibition of serotonin uptake.[](https://www.nature.com/articles/s41467-020-15292-y)[](https://pubmed.ncbi.nlm.nih.gov/27665061/)\n\nAs a racemic mixture of (R)- and (S)-enantiomers, citalopram's SSRI activity is predominantly attributable to the (S)-enantiomer (escitalopram), which inhibits serotonin uptake with approximately 167-fold greater potency than the (R)-enantiomer (IC\u003csub\u003e50\u003c/sub\u003e values of ~0.6 nM versus ~100 nM, respectively).[](https://www.clinpgx.org/pathway/PA164713429)[](https://pubmed.ncbi.nlm.nih.gov/15695064/) The (R)-enantiomer binds with lower affinity to the orthosteric site and may functionally antagonize the (S)-enantiomer's effects both in vitro and in vivo, potentially by interfering with allosteric modulation or SERT trafficking, which explains why the purified (S)-enantiomer exhibits superior efficacy and tolerability in clinical studies.[](https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0705738)[](https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2006.pto_295.x) This enantioselective pharmacology underscores the contribution of stereochemistry to citalopram's overall mechanism, with the racemic formulation's mixed effects possibly limiting its potency compared to escitalopram.[](https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/)[](https://www.researchgate.net/figure/The-two-enantiomers-of-citalopram-Citalopram-is-a-racemate_fig1_8546695)\n\n### Pharmacokinetics and Metabolism\n\n![Citalopram metabolism pathway](./_assets_/Citalopram_metabolism.png)\nCitalopram is rapidly absorbed following oral administration, with peak plasma concentrations achieved 1 to 4 hours after dosing and an absolute bioavailability of approximately 80%.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf) The pharmacokinetics exhibit linearity and dose proportionality across the 10 to 60 mg daily range, with steady-state concentrations attained within one week of once-daily dosing.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf)[](https://go.drugbank.com/drugs/DB00215)\n\nCitalopram distributes widely throughout the body, with a volume of distribution of about 12 L/kg, indicating extensive extravascular tissue binding.[](https://go.drugbank.com/drugs/DB00215) Plasma protein binding is approximately 80%, primarily to alpha-1-acid glycoprotein.[](https://go.drugbank.com/drugs/DB00215) The drug crosses the blood-brain barrier and is present in breast milk.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\nMetabolism occurs predominantly in the liver via N-demethylation, yielding the primary metabolite N-desmethylcitalopram (DCIT), which possesses about one-third the serotonin reuptake inhibitory activity of the parent compound.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/) This process is mediated mainly by CYP2C19 and CYP3A4, with minor contributions from CYP2D6; further demethylation produces didesmethylcitalopram (DDCIT).[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/) Citalopram exists as a racemic mixture of R- and S-enantiomers, with the S-enantiomer responsible for most therapeutic effects and undergoing slower metabolism than the R-form.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/)\n\nElimination follows a mean terminal half-life of 35 hours (range 24 to 48 hours), with 12 to 23% excreted unchanged in urine and about 10% in feces; the balance is eliminated as metabolites.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/) In elderly patients, single-dose AUC and half-life increase by 30% and 50%, respectively, necessitating cautious dosing adjustments.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf) Hepatic impairment prolongs half-life, while pharmacokinetics remain largely unaltered in renal impairment or mild to moderate hepatic disease.[](https://go.drugbank.com/drugs/DB00215)\n\n## Clinical Efficacy and Evidence\n\n### Evidence for Major Depressive Disorder\n\nCitalopram hydrobromide received U.S. Food and Drug Administration (FDA) approval on July 17, 1998, for the treatment of major depressive disorder (MDD) in adults, predicated on efficacy demonstrated in placebo-controlled clinical trials of 4 to 6 weeks' duration involving outpatients meeting DSM-III or DSM-III-R criteria for MDD.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) In one pivotal 6-week fixed-dose study (Study 1), citalopram at 40 mg/day and 60 mg/day produced statistically significant reductions in Hamilton Depression Rating Scale (HAM-D) total scores compared to placebo, whereas 10 mg/day and 20 mg/day doses did not show clear separation from placebo; the 60 mg dose offered no additional benefit over 40 mg.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) A second key 4-week trial (Study 2) employed flexible dosing starting at 20 mg/day up to a maximum of 80 mg/day, yielding significant HAM-D improvements over placebo.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)\n\nA multicenter, placebo-controlled, fixed-dose trial in 650 outpatients with moderate-to-severe MDD further supported efficacy, particularly at 40 mg/day and 60 mg/day, which outperformed placebo on HAM-D, Montgomery-Ã…sberg Depression Rating Scale (MADRS), and Clinical Global Impressions (CGI) scales, including core symptoms such as depressed mood, melancholia, cognitive disturbances, and psychomotor retardation; lower doses (10 mg and 20 mg) showed consistent but less robust advantages, significant on select MADRS and HAM-D subscales.[](https://pubmed.ncbi.nlm.nih.gov/10665628/) Three additional placebo-controlled trials referenced in the FDA approval dossier did not demonstrate statistically significant differences versus placebo, highlighting variability across studies.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)\n\nA 2011 systematic review and meta-analysis of five published placebo-controlled trials (total n=1,010 for response; n=1,541 for symptom reduction) found citalopram significantly superior to placebo, with a relative risk of response of 1.42 (95% CI 1.17-1.73) and a Hedges' g effect size of -0.27 (95% CI -0.38 to -0.16) for symptom reduction on continuous scales, indicating modest but reliable benefits without significant heterogeneity (IÂ²=0% for symptoms; 50.9% for response). Remission data from two trials were inconclusive, with one showing benefit (RR=1.59, 95% CI 1.10-2.31). The analysis noted poor methodological reporting in included studies, all but one industry-sponsored, raising potential bias concerns, though results aligned with broader evidence.\n\nIn a 2018 network meta-analysis of 522 trials encompassing 116,477 adults with MDD, citalopram ranked among 21 antidepressants more efficacious than placebo on acute-phase response (odds ratio 1.52, 95% CI 1.30-1.78) and remission, with standardized mean differences indicating symptom reductions, albeit with smaller inter-drug differences and tolerability trade-offs.32802-7/fulltext) Long-term placebo-controlled maintenance trials (6 months) in responders to acute citalopram (fixed 20-40 mg or flexible 20-60 mg) demonstrated delayed relapse compared to placebo switch, supporting prophylactic utility.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) Efficacy appears dose-dependent, optimal at 20-40 mg/day for most patients, with current FDA guidance capping at 40 mg due to QT prolongation risks at higher doses.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://pubmed.ncbi.nlm.nih.gov/10665628/)\n\n### Evidence for Anxiety Disorders and Other Conditions\n\nCitalopram demonstrates modest efficacy in certain anxiety disorders, primarily supported by small-scale randomized controlled trials (RCTs) and open-label studies rather than large-scale meta-analyses confirming broad superiority over placebo. In generalized anxiety disorder (GAD), a double-blind RCT involving 36 elderly patients with late-life anxiety (mean age 76 years) found citalopram (20-40 mg/day) significantly reduced Hamilton Anxiety Rating Scale scores by 12.4 points compared to placebo's 7.7 points after 12 weeks, with 68% of citalopram-treated patients achieving response (â‰¥50% symptom reduction) versus 36% on placebo. However, this trial was limited by its small sample size and focus on older adults, and broader reviews note a paucity of large RCTs establishing citalopram's monotherapy efficacy for GAD in general populations. An open-label study of 20 GAD patients reported response rates of 85% with citalopram (up to 40 mg/day) over 8 weeks, including benefits in patients refractory to prior SSRIs, but lacked placebo control and randomization.[](https://pubmed.ncbi.nlm.nih.gov/15625213/)[](https://psychiatryonline.org/doi/full/10.1176/appi.ajp.162.1.146)[](https://www.psychiatrist.com/jcp/pharmacologic-treatment-anxiety-disorders-review-progress/)[](https://pubmed.ncbi.nlm.nih.gov/11981350/)\n\nFor social anxiety disorder, an 8-week open-label trial of citalopram (20-40 mg/day) in 21 patients with or without comorbid depression yielded significant reductions in Liebowitz Social Anxiety Scale scores (from 78 to 45), with 72% classified as responders, suggesting potential utility for both generalized and performance subtypes. A meta-analysis of pharmacological treatments for anxiety disorders indicated that citalopram did not significantly outperform controls in direct comparisons, unlike other SSRIs such as sertraline or escitalopram, highlighting inconsistent effect sizes across studies. Evidence for panic disorder remains anecdotal or extrapolated from SSRI class effects, with no dedicated large RCTs identified.[](https://www.sciencedirect.com/science/article/abs/pii/S0278584601002366)[](https://pubmed.ncbi.nlm.nih.gov/25932596/)\n\nBeyond core anxiety disorders, citalopram shows preliminary support for obsessive-compulsive disorder (OCD) as an off-label application, with level 1 evidence from RCTs affirming SSRI efficacy, including citalopram doses of 40-60 mg/day yielding Yale-Brown Obsessive Compulsive Scale reductions comparable to other agents like fluoxetine, though higher doses may enhance response in refractory cases without proportional safety risks. In posttraumatic stress disorder (PTSD), evidence is weak and insufficient for recommendation; guidelines cite inadequate placebo-controlled data for citalopram, with only modest symptom improvements in small cohorts and no FDA endorsement. Limited investigations also explore citalopram for premenstrual dysphoric disorder and substance-use-related anxiety, but these lack robust RCTs and are not standard indications. Overall, while citalopram's serotonin reuptake inhibition provides a mechanistic rationale for anxiolytic effects, its evidence base for non-depressive conditions is narrower than for escitalopram, with calls for larger trials to clarify comparative benefits and risks.[](https://www.camh.ca/en/professionals/treating-conditions-and-disorders/ocd/ocd---treatment/ocd---pharmacotherapy)[](https://www.sciencedirect.com/science/article/pii/S0010440X24000373)[](https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp)[](https://psychiatryonline.org/doi/10.1176/appi.focus.20200048)\n\n### Comparative Effectiveness, Limitations, and Critiques\n\nIn meta-analyses of antidepressants for major depressive disorder, citalopram demonstrates efficacy superior to placebo, with response rates approximately 50-60% versus 30-40% for placebo, though effect sizes are modest (standardized mean difference around 0.3).32802-7/fulltext) [](https://pubmed.ncbi.nlm.nih.gov/29477251/) Comparisons with other selective serotonin reuptake inhibitors (SSRIs) reveal minimal differences; for instance, citalopram shows similar improvements in Hamilton Depression Rating Scale scores to sertraline in randomized trials.[](https://www.sciencedirect.com/science/article/abs/pii/S0006322300009574) However, escitalopram, the S-enantiomer of citalopram, consistently outperforms the racemic mixture in achieving acute response (odds ratio 1.47, 95% CI 1.08-2.00) and remission, with meta-analyses estimating a mean treatment difference of 1.7 points on the Montgomery-Ã…sberg Depression Rating Scale at week 8.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4204633/) [](https://academic.oup.com/ijnp/article/14/2/261/696727) This superiority is attributed to the R-enantiomer in citalopram potentially antagonizing serotonergic effects, though direct head-to-head trials in severe depression confirm escitalopram's edge without proportional increases in adverse events.[](https://pubmed.ncbi.nlm.nih.gov/15107719/)\n\nLimitations include dose restrictions due to QT interval prolongation, a dose-dependent risk prompting FDA warnings in 2011 to cap daily doses at 40 mg overall and 20 mg for patients over 60 or with hepatic impairment, as higher doses confer arrhythmogenic potential without added efficacy benefits.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram) [](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) These caps may undermine effectiveness in non-responders requiring supratherapeutic levels, with electrocardiographic monitoring recommended for at-risk individuals.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6007721/) Citalopram also lacks efficacy for certain off-indication uses, such as reducing repetitive behaviors in autism spectrum disorders, where placebo-controlled trials showed no significant benefit over placebo.[](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/210271)\n\nCritiques highlight the low to very low quality of evidence in many comparative studies per GRADE criteria, stemming from publication bias, heterogeneity in trial designs, and short-term endpoints that overlook long-term outcomes like relapse or functional recovery.32802-7/fulltext) The racemic formulation's inclusion of the less active R-enantiomer is seen as inefficient compared to enantiopure alternatives like escitalopram, potentially justifying preferences for the latter in guidelines despite similar tolerability profiles.[](https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05382-8) Broader SSRI critiques, applicable to citalopram, question overestimation of benefits relative to harms in real-world settings, where placebo responses and natural remission rates (up to 30-50% within months) inflate perceived advantages, though citalopram-specific data align with class-wide modest number-needed-to-treat values of 7-10 for response.[](https://www.acpjournals.org/doi/10.7326/0003-4819-155-11-201112060-00009)\n\n## Clinical Uses\n\n### Approved Indications\n\nCitalopram, sold under the brand name Celexa among others, received initial U.S. Food and Drug Administration (FDA) approval on July 17, 1998, for the treatment of major depressive disorder (MDD) in adults.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) This indication is supported by clinical trials demonstrating efficacy in reducing depressive symptoms, as measured by standardized scales such as the Hamilton Depression Rating Scale.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) The FDA has not approved citalopram for pediatric use, bipolar depression, or any other psychiatric conditions, reflecting limitations in trial data for these populations.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf)\n\nIn the European Union, citalopram is authorized by the European Medicines Agency (EMA) for the treatment of depressive illness in adults, with marketing authorizations granted to various national agencies following centralized assessments.[](https://www.ema.europa.eu/en/medicines) This approval aligns with the FDA's focus on MDD but excludes extensions to anxiety disorders or other off-label applications without additional evidence. Regulatory bodies emphasize that approvals are based on randomized controlled trials showing statistically significant improvements over placebo in adult MDD cohorts, typically over 6-8 weeks of treatment.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Variations exist in other jurisdictions; for instance, some countries approve it for panic disorder, but these are not universally endorsed by major agencies like the FDA or EMA.[](https://go.drugbank.com/drugs/DB00215)\n\n### Off-Label Applications\n\nCitalopram is employed off-label for various anxiety disorders, including panic disorder and obsessive-compulsive disorder (OCD), where selective serotonin reuptake inhibitors (SSRIs) as a class demonstrate efficacy comparable to approved agents, though specific randomized controlled trials (RCTs) for citalopram are limited. In panic disorder, open-label and small-scale studies report response rates of 60-70% after 8-12 weeks at doses of 20-40 mg/day, with reductions in panic frequency and anticipatory anxiety, but larger RCTs are needed to confirm superiority over placebo.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) For OCD, evidence from meta-analyses of SSRIs supports moderate symptom reduction (Yale-Brown Obsessive Compulsive Scale improvements of 25-35%), with citalopram showing similar outcomes to fluoxetine or sertraline in comparative trials, often requiring doses up to 40-60 mg/day for adequate response; however, FDA approval for OCD is absent, and augmentation with antipsychotics may be necessary for refractory cases.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9645290/)[](https://www.sciencedirect.com/science/article/pii/S0010440X24000373)\n\nPost-traumatic stress disorder (PTSD) represents another psychiatric off-label application, inferred from citalopram's efficacy in comorbid depression and anxiety; small RCTs indicate modest improvements in hyperarousal and intrusion symptoms (e.g., 20-30% reduction on Clinician-Administered PTSD Scale), but evidence is weaker than for sertraline or paroxetine, with no large-scale endorsement in guidelines.[](https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/) Beyond anxiety spectrum conditions, citalopram is used for premenstrual dysphoric disorder (PMDD), where intermittent dosing (e.g., 20 mg/day during luteal phase) yields response rates of 50-60% in RCTs, outperforming placebo in mood and irritability metrics, aligning with SSRI class benefits.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://www.aafp.org/pubs/afp/issues/2003/0801/p498.html)\n\nNon-psychiatric off-label uses include postmenopausal hot flashes, with RCTs demonstrating 40-50% reduction in frequency and severity at 10-20 mg/day versus placebo, attributed to serotonergic modulation of thermoregulation, though long-term data are sparse and estrogen therapy remains first-line.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) For alcohol use disorder, adjunctive citalopram (20-40 mg/day) in RCTs reduces craving and relapse rates by 20-30% in early abstinence, particularly in patients with comorbid depression, but standalone efficacy is inconsistent without psychotherapy.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) In coronary artery disease patients, low-dose citalopram (10-20 mg/day) mitigates post-myocardial infarction depression and improves cardiac outcomes in secondary prevention trials, such as the SADHART-CHF study analog, by lowering inflammatory markers and enhancing adherence.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Overall, while these applications leverage citalopram's favorable tolerability profile, evidence levels vary from moderate (e.g., PMDD, hot flashes) to preliminary, with risks of QT prolongation necessitating ECG monitoring at higher doses.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC9878961/)\n\n## Administration and Dosage\n\n### Dosing Guidelines\n\nCitalopram is administered orally as tablets or oral solution, typically once daily with or without food, in the morning or evening.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf) For adults with major depressive disorder, the initial recommended dose is 20 mg once daily, with potential increase to 40 mg once daily after at least one week if clinical response is inadequate.[](https://www.drugs.com/dosage/citalopram.html) [](https://reference.medscape.com/drug/celexa-citalopram-342958) Doses exceeding 40 mg per day are not recommended due to increased risk of dose-dependent QT interval prolongation, which can lead to torsades de pointes and sudden death.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related)\n\nIn patients over 60 years of age, the maximum recommended dose is 20 mg per day, starting at 20 mg once daily, to mitigate QT prolongation risk.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) [](https://www.mayoclinic.org/drugs-supplements/citalopram-oral-route/description/drg-20062980) For individuals with hepatic impairment, the maximum dose is also limited to 20 mg per day, often starting at a lower dose such as 10-20 mg to account for reduced metabolism.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) [](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf) No dosage adjustment is required for mild to moderate renal impairment, but caution is advised in severe cases with monitoring for accumulation.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\nThe following table summarizes dosing recommendations by population:\n\n| Population                  | Initial Dose       | Titration/Maintenance Dose | Maximum Dose |\n|-----------------------------|--------------------|----------------------------|--------------|\n| Adults (18-60 years)        | 20 mg once daily  | Increase to 40 mg after â‰¥1 week if needed | 40 mg/day   |\n| Elderly (\u003e60 years)         | 20 mg once daily  | No increase beyond initial | 20 mg/day   |\n| Hepatic impairment          | 10-20 mg once daily | Up to 20 mg               | 20 mg/day   |\n| Mild-moderate renal impairment | 20 mg once daily | As for adults             | 40 mg/day   |\n\nDosing should be individualized based on response and tolerability, with gradual titration to minimize adverse effects; discontinuation involves tapering to prevent withdrawal symptoms.[](https://www.drugs.com/dosage/citalopram.html) [](https://www.mayoclinic.org/drugs-supplements/citalopram-oral-route/description/drg-20062980) CYP2C19 poor metabolizers may require dose reduction to 20 mg maximum due to elevated plasma levels and QT risk.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) Baseline ECG is recommended for patients with cardiac risk factors before initiating higher doses.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\n### Formulation and Pharmacotherapeutic Considerations\n\n![Citalopram tablets](._assets_/Citalopram20-40-2.jpg)Citalopram hydrobromide is commercially available in immediate-release oral formulations, including film-coated tablets in strengths of 10 mg, 20 mg, and 40 mg, and an oral solution at a concentration of 10 mg per 5 mL.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037%2C021046s015lbl.pdf) These dosage forms are designed for once-daily administration, with bioavailability of approximately 80 percent and absorption unaffected by food intake.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) The tablet and oral solution are bioequivalent, facilitating interchangeable use for dose titration.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037%2C021046s015lbl.pdf)[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\nPharmacotherapeutic considerations emphasize dose limitations to mitigate risks associated with the drug's racemic composition, where the S-enantiomer drives selective serotonin reuptake inhibition while both enantiomers contribute to cardiac effects.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) The maximum recommended dose is 40 mg daily for most adults, reduced to 20 mg in patients over 60 years, those with hepatic impairment, or CYP2C19 poor metabolizers due to prolonged QT interval at higher exposures.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) Concomitant CYP2C19 inhibitors like cimetidine necessitate dose adjustments to avoid accumulation.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) The oral solution offers advantages for patients with swallowing difficulties or requiring precise low-dose adjustments, though some non-U.S. drop formulations may exhibit up to 25 percent higher bioavailability, requiring dose equivalence verification.[](https://www.medicines.org.uk/emc/product/3349/smpc)[](https://www.hpft.nhs.uk/media/1942/19-citalopram-tabs-or-drops-equivalent-doses-march-2012.pdf) Formulation selection should prioritize patient adherence and minimize excipient-related issues, such as alcohol content in certain solutions.[](https://www.medicines.org.uk/emc/product/3349/smpc)\n\n## Safety Profile\n\n### Common Adverse Effects\n\nThe most frequently reported adverse effects of citalopram in placebo-controlled clinical trials, defined as those occurring in at least 5% of patients and at least twice the rate observed with placebo, are primarily gastrointestinal, central nervous system, and autonomic in nature. These effects were derived from pooled data involving 1,063 citalopram-treated patients compared to 446 on placebo, across trials up to 6 weeks in duration.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) Incidence rates vary by dose, with higher doses associated with increased severity for effects such as somnolence and sexual dysfunction.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\n| Adverse Effect              | Incidence in Citalopram Patients (%) | Incidence in Placebo Patients (%) |\n|-----------------------------|--------------------------------------|-----------------------------------|\n| Nausea                      | 21                                   | 14                                |\n| Dry mouth                   | 20                                   | 14                                |\n| Somnolence                  | 18                                   | 10                                |\n| Insomnia                    | 15                                   | 14                                |\n| Increased sweating          | 11                                   | 3                                 |\n| Tremor                      | 8                                    | 6                                 |\n| Diarrhea                    | 8                                    | 5                                 |\n| Ejaculation disorder (males)| 6                                    | 1                                 |\n| Dyspepsia                   | 5                                    | 3                                 |\n| Fatigue                     | 5                                    | 3                                 |\n| Upper respiratory infection | 5                                    | 3                                 |\n| Rhinitis                    | 5                                    | 3                                 |[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)\n\nThese effects often resolve with continued treatment or dose adjustment, though gastrointestinal symptoms like nausea typically emerge early and may affect adherence if persistent.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Sexual side effects, such as delayed ejaculation, are particularly notable in males and dose-related, occurring in up to 6% at standard therapeutic doses.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) Overall, adverse reactions affect up to 10% of users sufficiently to warrant discontinuation in some cases, underscoring the need for monitoring during initiation.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\n### Serious Risks Including Suicidality\n\nCitalopram, like other selective serotonin reuptake inhibitors (SSRIs), carries a boxed warning from the U.S. Food and Drug Administration (FDA) for an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults aged up to 24 years during the initial months of treatment or dose adjustments.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) [](https://www.ncbi.nlm.nih.gov/books/NBK482222/) This risk stems from pooled analyses of short-term placebo-controlled trials showing a doubling of suicidality rates (from 2 to 4 per 1,000 patients) in pediatric and young adult populations, though completed suicides were rare.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) Citalopram is not approved for use in patients under 18 years due to this elevated risk and lack of demonstrated efficacy in pediatric depression trials.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\nIn adults over 24 years, meta-analyses of clinical trials indicate no overall increase in suicidality with SSRIs, including citalopram, and evidence suggests a potential reduction in suicide risk among older adults (over 65 years), possibly due to alleviation of depressive symptoms outweighing activation effects.[](https://www.nature.com/articles/s41386-021-01179-z) [](https://www.bmj.com/content/339/bmj.b2880) Observational studies and long-term data reinforce that SSRI initiation does not elevate completed suicide rates in adults, though monitoring for worsening depression or emergent suicidality remains essential, especially in the first weeks of therapy.[](https://journals.lww.com/ebp/fulltext/2009/10000/does_the_initiation_of_an_ssri_for_depression.14.aspx) [](https://www.medrxiv.org/content/10.1101/2020.05.11.20098178.full)\n\nBeyond suicidality, citalopram poses a dose-dependent risk of QT interval prolongation, which can lead to torsades de pointes, ventricular tachycardia, or sudden cardiac death, prompting FDA recommendations against doses exceeding 40 mg daily (or 20 mg in patients over 60, those with hepatic impairment, or CYP2C19 poor metabolizers).[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) [](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram) This electrocardiographic effect arises from citalopram's inhibition of cardiac potassium channels, with post-marketing reports documenting rare but serious arrhythmias, particularly at higher doses or in predisposed individuals (e.g., those with hypokalemia, bradycardia, or concomitant QT-prolonging drugs).[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) Screening via ECG is advised in at-risk patients, and alternatives like escitalopram may carry lower cardiac risk.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related)\n\nOther serious risks include severe hyponatremia (often syndrome of inappropriate antidiuretic hormone secretion), which occurs in up to 0.5-1% of users, predominantly elderly females, manifesting as confusion, seizures, or coma and necessitating discontinuation.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Abnormal bleeding events, such as gastrointestinal hemorrhage, are elevated due to serotonin-mediated platelet dysfunction, with odds ratios up to 1.5-2 in meta-analyses, warranting caution in patients on anticoagulants or NSAIDs.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) Seizures, though uncommon (incidence ~0.3%), and acute angle-closure glaucoma in susceptible individuals represent additional contraindications.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) All patients require close monitoring for these adverse events, with risk-benefit assessment individualized based on comorbidities.\n\n### Long-Term Effects and Discontinuation\n\nLong-term use of citalopram, typically administered at doses of 20-40 mg daily for maintenance therapy in major depressive disorder, has demonstrated efficacy in preventing depressive relapse among elderly patients and those with highly recurrent unipolar depression, with studies showing sustained remission rates over 24-28 months when continued post-acute response.[](https://pubmed.ncbi.nlm.nih.gov/12091260/)[](https://pubmed.ncbi.nlm.nih.gov/11740983/) In a randomized trial involving elderly participants, citalopram maintenance reduced recurrence risk compared to placebo, with good tolerability reported over extended periods.[](https://mentalhealth.bmj.com/content/6/1/24) However, animal models indicate potential neurotoxic effects from prolonged exposure, including male-specific impairments in motor function, learning, and memory, alongside biochemical alterations such as reduced serotonin content and metabolite levels in brain regions.[](https://pubmed.ncbi.nlm.nih.gov/35985052/)[](https://pubs.acs.org/doi/abs/10.1021/acs.est.2c01514)[](https://pubmed.ncbi.nlm.nih.gov/20946930/)\n\nPersistent adverse effects associated with long-term selective serotonin reuptake inhibitor (SSRI) therapy, including citalopram, encompass sexual dysfunction (reported in up to 71.8% of long-term users), weight gain (65.3%), and emotional numbing, which may contribute to treatment discontinuation despite ongoing therapeutic benefits.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4970636/) Cardiovascular risks, such as QT interval prolongation leading to arrhythmias, are heightened at doses exceeding 40 mg daily, prompting FDA recommendations against such use, particularly in patients with predisposing factors like heart failure or congenital long QT syndrome.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) Observational data link extended SSRI exposure to increased cardiovascular disease risk, potentially doubling odds in some cohorts, though causality remains debated due to confounding factors like underlying depression severity.[](https://www.bristol.ac.uk/primaryhealthcare/news/2022/adverse-health-outcomes-associated-with-long-term-antidepressant-use.html)\n\nDiscontinuation of citalopram often precipitates withdrawal symptoms characteristic of SSRI discontinuation syndrome, affecting 33-56% of users per systematic reviews, with manifestations including dizziness, nausea, flu-like symptoms, sensory disturbances, and anxiety emerging within days of cessation and persisting for weeks even with tapering.[](https://www.psychiatryonline.org/doi/10.1176/appi.pn.2025.09.9.1)[](https://pubmed.ncbi.nlm.nih.gov/25721705/) Severe symptoms occur in approximately 2-15% of cases, underscoring the need for gradual dose reduction over weeks to months to mitigate intensity, as abrupt stops exacerbate risks.[](https://www.jwatch.org/na57759/2024/07/30/antidepressant-discontinuation-syndrome-meta-analysis)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4722507/) Relapse rates are markedly higher post-discontinuation (up to 50% within months) compared to maintenance, as evidenced in primary care trials where citalopram continuation outperformed placebo in sustaining remission.[](https://www.nejm.org/doi/full/10.1056/NEJMoa2106356) Case reports specific to citalopram highlight atypical presentations like pronounced psychological distress, reinforcing the syndrome's clinical burden beyond mere relapse.[](https://www.pulsus.com/scholarly-articles/an-interesting-discontinuation-syndrome-with-citalopram-a-case-report.pdf) Guidelines emphasize monitoring during taper, as symptoms can mimic recurrence, complicating attribution.[](https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2824%2900133-0/fulltext)\n\n## Drug Interactions\n\n### Major Interactions\n\nCitalopram is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including reversible MAOIs such as linezolid or intravenous methylene blue, due to the risk of serious, potentially fatal serotonin syndrome; at least 14 days should elapse between discontinuing an MAOI and initiating citalopram, and vice versa.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf) Concomitant use with pimozide is also contraindicated, as citalopram inhibits pimozide metabolism via CYP2D6 and both drugs prolong the QT interval, increasing the risk of torsades de pointes and sudden death.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020822s29lbl.pdf)[](https://assets.hpra.ie/products/Human/24269/LicenseSPC_PA1063-017-001_28052013171216.pdf)\n\nOther serotonergic agents, such as SNRIs, TCAs, triptans, tramadol, and St. John's wort, can potentiate serotonin effects when combined with citalopram, elevating the risk of serotonin syndrome characterized by hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes; such combinations require careful monitoring or avoidance.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) Pharmacokinetic interactions arise from citalopram's metabolism primarily via CYP2C19, with lesser roles for CYP3A4 and CYP2D6; strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole) can increase citalopram exposure by up to 2-fold, necessitating dose reduction to a maximum of 20 mg/day in poor CYP2C19 metabolizers or with potent inhibitors to mitigate QT prolongation and other adverse effects.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\nDrugs that prolong the QT interval, including class IA and III antiarrhythmics (e.g., quinidine, amiodarone), antipsychotics, and certain antibiotics (e.g., erythromycin), should be avoided or used with extreme caution alongside citalopram, as the combination heightens the risk of ventricular arrhythmias, particularly at doses exceeding 40 mg/day or in patients with predisposing factors like hypokalemia or congenital long QT syndrome.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related)\n\n![Citalopram metabolism pathway](./_assets_/Citalopram_metabolism.png)\n\n### Serotonin Syndrome and Related Risks\n\nCitalopram, a selective serotonin reuptake inhibitor, elevates synaptic serotonin concentrations, predisposing patients to serotonin syndromeâ€”a potentially fatal condition involving excessive serotonergic activityâ€”particularly when combined with other serotonergic medications.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/) This syndrome manifests as a clinical triad of altered mental status (e.g., agitation, confusion), autonomic instability (e.g., tachycardia, hyperthermia, diaphoresis), and neuromuscular excitation (e.g., tremors, hyperreflexia, clonus).[](https://www.ncbi.nlm.nih.gov/books/NBK482377/) While therapeutic doses of citalopram monotherapy infrequently precipitate severe serotonin syndrome, the risk escalates with polypharmacy involving agents like monoamine oxidase inhibitors (MAOIs), where concurrent administration has been linked to serotonergic hyperactivity in clinical evidence.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3865832/)\n\nDocumented cases highlight interactions amplifying this hazard: for instance, co-administration with fentanyl has been deemed a probable cause of serotonin syndrome based on the Naranjo adverse drug reaction probability scale.[](https://pubmed.ncbi.nlm.nih.gov/17381671/) Similarly, combinations with oxycodone or tramadol have resulted in syndrome onset, often tied to elevated plasma levels of the interacting drugs.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3368298/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4276375/) Overdose scenarios further compound the risk, with reports of severe serotonin syndrome following single-agent citalopram ingestion, especially in individuals with impaired metabolism due to genetic polymorphisms in cytochrome P450 enzymes like CYP2C19.[](https://www.sciencedirect.com/science/article/abs/pii/S0735675719304176) Isolated instances of syndrome emergence after initial low-dose citalopram (e.g., 20 mg) underscore rarity but potential vulnerability in susceptible patients.[](https://www.sciencedirect.com/science/article/abs/pii/S0161813X0700085X)\n\nRelative to other classes, SSRIs including citalopram are associated with milder serotonin syndrome manifestations compared to MAOIs or their combinations, reflecting dose-dependent toxicity rather than inherent high potency for severe outcomes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6184959/) Management entails immediate discontinuation of serotonergic agents, supportive care, and, in severe cases, serotonin antagonists like cyproheptadine; however, no prospective trials quantify citalopram-specific incidence, relying instead on case series and pharmacovigilance data. Related risks encompass exacerbated serotonergic effects in overdose, such as seizures or coma, and cautionary avoidance of concurrent use with triptans, St. John's wort, or linezolid to mitigate cumulative serotonin accumulation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4469720/)[](https://www.uspharmacist.com/article/drug-induced-serotonin-syndrome)\n\n## Use in Special Populations\n\n### Pregnancy, Lactation, and Reproductive Effects\n\nCitalopram, classified by the FDA as Pregnancy Category C, has demonstrated adverse effects on embryo/fetal development and postnatal outcomes in animal reproduction studies, including increased embryo/fetal lethality and skeletal abnormalities at doses approximately 8 times the maximum recommended human dose, though potential risks to humans remain uncertain due to limited controlled data.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf)[](https://www.drugs.com/pregnancy/citalopram.html) Human studies indicate no substantial increase in major congenital malformations with first-trimester exposure to citalopram specifically, unlike paroxetine which carries a slight cardiac risk, but overall selective serotonin reuptake inhibitor (SSRI) use may associate with modest elevations in preterm birth (relative risk 1.43) and low birth weight.[](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2769190)[](https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/antidepressants/art-20046420)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10590209/) Third-trimester exposure heightens risks of neonatal adaptation syndrome, manifesting as irritability, respiratory distress, and poor feeding in up to 30% of exposed infants, potentially linked to serotonin discontinuation effects rather than toxicity, with persistent pulmonary hypertension of the newborn (PPHN) occurring rarely (odds ratio around 2-3 for SSRIs generally).[](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1193-5)[](https://www.ajog.org/article/S0002-9378%2818%2930709-9/fulltext) Longer-term follow-up reveals possible associations with delayed motor development and elevated ADHD symptoms in exposed children, though confounding from maternal depression complicates causality attribution.[](https://publications.aap.org/pediatrics/article/142/1/e20180356/37500/Prenatal-Antidepressant-Exposure-and-Child-Motor)[](https://www.nature.com/articles/s41398-023-02441-2) Discontinuation during pregnancy may reduce certain neonatal hospitalization risks compared to continuation, but untreated maternal depression elevates preterm delivery and other complications, necessitating individualized risk-benefit assessment.[](https://www.sciencedirect.com/science/article/pii/S0165178124005596)\n\nIn lactation, citalopram transfers into breast milk at low levels, typically 0.7-7.9% of the maternal weight-adjusted dose, rendering it generally compatible with breastfeeding per safety scoring systems, though monitoring for infant sedation, irritability, or weight gain issues is advised.[](https://www.ncbi.nlm.nih.gov/books/NBK501185/)[](https://www.sps.nhs.uk/articles/using-ssri-antidepressants-during-breastfeeding/) Limited case reports document rare instances of infant drowsiness and feeding difficulties, but population studies of exposed infants show no consistent adverse neurodevelopmental effects, with alternatives like sertraline preferred for minimal milk transfer.[](https://mothertobaby.org/fact-sheets/citalopramescitalopram-celexalexapro-pregnancy/)[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1414677/full) Experts recommend the lowest effective maternal dose and avoiding nursing during peak drug absorption to mitigate potential exposure.[](https://pubmed.ncbi.nlm.nih.gov/10664835/)\n\nRegarding reproductive effects, citalopram may impair female fertility through mechanisms like elevated prolactin and corticosterone in animal models, leading to ovarian histopathology and infertility in rodents, but human evidence is inconsistent and often confounded by underlying depression.[](https://www.sciencedirect.com/science/article/abs/pii/S0890623825000309) In women, SSRI exposure associates with reduced conception probability independent of depression severity in some cohorts, potentially halving pregnancy rates, though untreated psychiatric illness similarly detrimentally affects fertility outcomes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4965341/) For males, citalopram exposure links to reversible declines in sperm motility and concentration, with quality normalizing post-discontinuation, but does not appear to broadly compromise reproductive function at therapeutic doses.[](https://mothertobaby.org/fact-sheets/citalopramescitalopram-celexalexapro-pregnancy/)[](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1567863/full) Overall, while animal data suggest caution, prospective human studies emphasize minimal direct impact beyond depression-related factors.[](https://womensmentalhealth.org/posts/antidepressants-impact-fertility/)\n\n### Pediatrics and Adolescents\n\nCitalopram is not approved by the U.S. Food and Drug Administration (FDA) for use in pediatric patients, including children and adolescents, due to insufficient evidence establishing safety and efficacy for major depressive disorder (MDD) or other indications in this population.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf) Clinical trials, such as the CIT-MD-18 study involving 174 participants aged 7-17 years with MDD, reported that citalopram (20-40 mg/day) led to greater reductions in depressive symptoms on the Children's Depression Rating Scale-Revised compared to placebo over 8 weeks, with response rates of 38.6% versus 19.2%.[](https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.6.1079) However, subsequent analyses and systematic reviews have questioned the robustness of these findings, noting small effect sizes, potential publication bias, and failure to demonstrate sustained benefits or superiority in broader meta-analyses of antidepressants for adolescent depression.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC3222577/) For instance, a network meta-analysis of antidepressants found limited evidence supporting citalopram's efficacy relative to other selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, which has FDA approval for pediatric MDD.[](https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2820%2930137-1/fulltext)\n\nSafety concerns predominate in pediatric use, with a class-wide FDA black box warning for all antidepressants, including citalopram, highlighting an increased risk of suicidality in children, adolescents, and young adults. Pooled data from 24 pediatric trials (over 4,400 patients) across SSRIs showed a twofold higher rate of suicidal ideation or behavior (4% versus 2% with placebo) during initial treatment months, though no completed suicides occurred.[](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications) In the CIT-MD-18 trial, citalopram was associated with higher rates of treatment-emergent suicidality (emergent suicidality risk ratio 2.19) and other adverse events like insomnia, asthenia, and rhinitis compared to placebo, prompting re-evaluation and non-approval.[](https://journals.sagepub.com/doi/10.3233/JRS-160671) Guidelines from organizations such as the American Academy of Child and Adolescent Psychiatry (AACAP) and the GLAD-PC toolkit for primary care recommend psychotherapy as first-line for mild-to-moderate adolescent depression, reserving SSRIs like fluoxetine for moderate-to-severe cases with close monitoring; citalopram is not endorsed as a preferred agent due to equivocal efficacy data and heightened risks.[](https://publications.aap.org/pediatrics/article/141/3/e20174082/37654/Guidelines-for-Adolescent-Depression-in-Primary) Off-label prescribing occurs, particularly for obsessive-compulsive disorder (OCD) where preliminary data suggest possible benefits, but evidence remains weaker than for approved SSRIs like sertraline or fluoxetine.[](https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/citalopram/263A565EEAEAF8962B276D8763FDC922)\n\nLong-term data are scarce, with no large-scale studies confirming sustained efficacy or safety in youth. Discontinuation may exacerbate withdrawal symptoms or depressive relapse, and monitoring for activation syndromeâ€”manifesting as agitation or impulsivityâ€”is advised if used off-label.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6738970/) Overall, while some short-term symptom relief has been observed in select trials, the risk-benefit profile does not support routine use in pediatrics without specialist oversight, prioritizing evidence-based alternatives like cognitive-behavioral therapy combined with approved pharmacotherapies where indicated.[](https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-224-depression-children-final-report.pdf)\n\n### Elderly and Overdose Scenarios\n\nIn elderly patients over 60 years of age, the maximum recommended dose of citalopram is 20 mg once daily due to heightened risk of dose-dependent QT interval prolongation, which can precipitate torsades de pointes, ventricular tachycardia, or sudden cardiac death.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf)[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) This age-related vulnerability stems from reduced drug clearance and metabolism, exacerbating electrocardiographic changes observed at doses exceeding 20 mg.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6007721/) Despite these risks, citalopram exhibits efficacy comparable to other antidepressants for geriatric depression, with studies showing response rates up to 65% at doses of 20-40 mg in patients with a mean age of 70.7 years, though higher doses may worsen cognition in those with Alzheimer's-related agitation.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC6607952/) Additional adverse effects in this population include hyponatremia, increased fall risk from orthostasis, and potential associations with incident dementia, necessitating careful monitoring of serum sodium, electrolytes, and cognitive status.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4760914/)\n\nCitalopram overdose primarily manifests as serotonin excess symptoms such as nausea, vomiting, drowsiness, tremor, and hyperreflexia, alongside cardiovascular effects including QT prolongation, bradycardia, and arrhythmias like torsades de pointes, particularly with ingestions exceeding 600 mg.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)[](https://litfl.com/ssri-toxicity/) Seizures occur in up to 5-10% of cases, while coma is uncommon unless co-ingestants are involved; fatalities are rare but linked to refractory arrhythmias or aspiration.[](https://emedicine.medscape.com/article/821737-treatment) Management emphasizes supportive care, including airway protection, intravenous fluids, and benzodiazepines for seizures or agitation; gastrointestinal decontamination with 50 g activated charcoal is advised if ingestion was within 4 hours and the patient remains alert for \u003e600 mg citalopram.[](https://litfl.com/ssri-toxicity/) Continuous ECG monitoring is mandatory for at least 24 hours in symptomatic patients or those with doses \u003e600 mg, extending to 13 hours minimum for ingestions \u003e1000 mg, with sodium bicarbonate or magnesium sulfate for QTc \u003e500 ms or torsades.[](https://litfl.com/citalopram-overdose/)[](https://emedicine.medscape.com/article/821737-treatment) Cytochrome P450 inhibition is not a primary concern in overdose, and hemodialysis is ineffective due to high protein binding and large volume of distribution.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\n## History and Development\n\n### Discovery and Clinical Trials\n\nCitalopram was synthesized in 1972 by chemists at the Danish pharmaceutical company H. Lundbeck A/S, initially designated as Lu 10-171, as part of efforts to develop selective serotonin reuptake inhibitors following the firm's earlier work on antidepressants like Saroten launched in the 1960s.[](https://www.imrpress.com/journal/AP/26/2/10.31083/AP40037/htm)[](https://www.lundbeck.com/us/about-us/this-is-lundbeck/our-history) The compound's structure, a racemic mixture of R- and S-enantiomers, was patented by Lundbeck prior to clinical evaluation, targeting enhanced serotonin reuptake inhibition with reduced affinity for other neurotransmitter systems compared to prior tricyclic antidepressants.[](https://www.chm.bris.ac.uk/motm/citalopram/citalopramh.htm)\n\nClinical development spanned approximately 15 years post-synthesis, with initial trials commencing in the late 1970s. An early open-label study involving depressive patients, published in 1980, reported preliminary evidence of antidepressant efficacy at doses of 20-60 mg daily, prompting calls for controlled evaluations to confirm therapeutic value and safety.[](https://pubmed.ncbi.nlm.nih.gov/6935914/) Subsequent placebo-controlled and comparative trials in Europe during the 1980s demonstrated statistically significant improvements in Hamilton Depression Rating Scale scores versus placebo, with response rates around 50-60% in major depressive disorder cohorts, and a favorable side-effect profile dominated by nausea and dry mouth rather than anticholinergic effects.[](https://link.springer.com/article/10.1007/BF00606656)\n\nBy the late 1980s, aggregated data from multiple phase III trials supported regulatory approval in Denmark in 1989 as Cipramil for depressive illness, marking the first market introduction.[](https://www.lundbeck.com/us/about-us/this-is-lundbeck/our-history) Further international trials, including those bridging European and U.S. protocols, confirmed efficacy in anxiety-associated depression and led to approvals in over 70 countries by the early 1990s, with U.S. Food and Drug Administration authorization in 1998 as Celexa based on randomized, double-blind studies showing superiority over placebo in reducing depressive symptoms by week 4-6.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10197723/) These trials typically enrolled 100-400 participants per study, emphasizing outpatient settings and short-term efficacy endpoints of 6-8 weeks.[](https://www.sciencedirect.com/topics/chemistry/citalopram)\n\n### Regulatory Approvals and Patent Issues\n\nCitalopram hydrobromide was approved by the U.S. Food and Drug Administration (FDA) on July 17, 1998, for the treatment of major depressive disorder in adults, marketed as Celexa tablets by Forest Laboratories, Inc.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm) Subsequent formulations, including an oral solution, received approval on March 27, 2012, with revisions to labeling for safety updates.[](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021046Orig1s019.pdf) In 2011, the FDA issued warnings limiting the maximum daily dose to 40 mg due to risks of QT interval prolongation and added restrictions for patients over 60 or with hepatic impairment, reducing it to 20 mg.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram)\n\nIn the European Union, citalopram has been authorized nationally since 1989, initially in Denmark as Cipramil by H. Lundbeck A/S, with subsequent approvals in other member states for depression treatment.[](https://ogyei.gov.hu/kiseroirat/ph/ph_0000021931.pdf) The European Medicines Agency (EMA) oversees post-authorization safety updates, including alignment with FDA dose restrictions following cardiac risk assessments. No centralized marketing authorization exists, as it predates the EMA's mutual recognition procedures for many indications.\n\nThe compound patent for citalopram, held by Lundbeck, expired in 2003, enabling generic entry in the U.S. market by late 2004 after resolution of litigation challenges.[](https://www.drugs.com/availability/generic-celexa.html) Forest Laboratories faced Paragraph IV patent certifications from generic manufacturers, leading to suits under the Hatch-Waxman Act to defend exclusivity, with generics like those from Teva approved shortly after. In Europe, Lundbeck entered settlement agreements with generic firms (e.g., Ranbaxy, Barr) between 1999 and 2002, paying them to delay market entry despite the expiring compound patent, relying instead on secondary process patents of limited scope.[](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0307%2801%29)\n\nThese settlements prompted antitrust scrutiny; in 2013, the European Commission fined Lundbeck â‚¬93.8 million and generics â‚¬52.2 million total for restricting competition, classifying the deals as \"pay-for-delay\" schemes that artificially extended market dominance beyond valid patent protection.[](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0307%2801%29) The Court of Justice of the EU upheld the decision in 2021, affirming that such agreements, even amid genuine patent disputes, constituted restrictions by object under EU competition law when generics were potential competitors.[](https://curia.europa.eu/jcms/jcms/p1_3471475/fr/) Similar U.S. probes by the FTC examined reverse payments but did not result in penalties specific to citalopram, contrasting with Europe's broader application to secondary patents.\n\n## Societal and Regulatory Context\n\n### Prescribing Trends and Market Dynamics\n\nIn the United States, citalopram prescriptions reached approximately 14.8 million in 2023, reflecting sustained but declining use as a selective serotonin reuptake inhibitor (SSRI) primarily for major depressive disorder.[](https://www.statista.com/statistics/781811/citalopram-prescriptions-number-in-the-us/) Overall SSRI prescribing has contributed to a 109% increase in antidepressant utilization from 2010 to 2023, yet citalopram specifically exhibits a downward trajectory, with use decreasing among Medicare and Medicaid beneficiaries from 2015 to 2020.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC12360015/) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC11919847/)\n\nThis decline correlates with the 2011 U.S. Food and Drug Administration (FDA) warning limiting maximum daily doses to 40 mg due to dose-dependent QT interval prolongation risks, revised in 2012 to 20 mg for patients over 60 years old.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) Studies confirm reduced high-dose prescribing post-warning, with regulatory changes achieving notable decreases in supratherapeutic use, though approximately one-third of older adults remained on higher doses in some cohorts, alongside unintended increases in anxiolytic and sedative co-prescribing and healthcare utilization.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC4468881/) [](https://www.sciencedirect.com/science/article/abs/pii/S1064748117304736) [](https://pubmed.ncbi.nlm.nih.gov/28012712/)\n\nConcurrent shifts favor escitalopram, the S-enantiomer of citalopram approved in 2002, which has seen rising prescription rates in parallel databases, potentially driven by marketing strategies, perceived superior efficacy in meta-analyses (e.g., 1.7-point MADRS score advantage), and lower doses for equivalent effects.[](https://www.researchgate.net/publication/370609774_Rise_of_escitalopram_and_the_fall_of_citalopram) [](https://academic.oup.com/ijnp/article/14/2/261/696727) Citalopram's racemic structure, including the less active R-enantiomer, may contribute to this preference amid evidence of escitalopram's better tolerability profile.[](https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/)\n\nMarket dynamics shifted markedly after generic entry in October 2004, following Celexa (branded citalopram) approval in 1998, eroding brand-name revenues through saturation and competition.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC2719790/) Global citalopram revenues, largely from generics, peaked at an estimated $1.2 billion in 2016 before stabilizing amid broader SSRI options.[](https://www.drugpatentwatch.com/p/generic-api/CITALOPRAM%2BHYDROBROMIDE) Generic pricing advantages persist, with citalopram remaining cost-competitive against escitalopram, though evergreening tacticsâ€”such as escitalopram's promotion as an optimized formulationâ€”have influenced prescriber behavior and market share allocation.[](https://www.researchgate.net/publication/370609774_Rise_of_escitalopram_and_the_fall_of_citalopram) Projections indicate modest compound growth to $1.8 billion by 2033, tempered by prescription declines and regulatory scrutiny.[](https://www.verifiedmarketreports.com/product/citalopram-market/)\n\n### Controversies Including Overprescription and Public Health Debates\n\nIn 2011, the U.S. Food and Drug Administration (FDA) issued a safety communication warning that citalopram causes dose-dependent QT interval prolongation, increasing the risk of potentially fatal abnormal heart rhythms such as torsades de pointes, and advised against prescribing doses exceeding 40 mg per day overall or 20 mg per day in patients over 60 years old or with hepatic impairment.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram) This followed post-marketing reports and electrocardiographic data indicating a mean QTc increase of 8.5 ms at 20 mg, 18.5 ms at 40 mg, and 20.3 ms at 60 mg, with recommendations to avoid use in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, or recent myocardial infarction.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram) The warning was revised in 2012 and further in 2017, softening contraindications to \"not recommended\" for higher doses while emphasizing ECG monitoring and risk factor avoidance, amid concerns that abrupt changes could disrupt treatment for millions of users.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related)\n\nSubsequent research has sparked debate over the warning's clinical significance and potential for overcaution. A 2013 observational study of over 38,000 patients found no elevated risks of ventricular arrhythmia or all-cause mortality with citalopram doses above 40 mg per day compared to other antidepressants, even after adjusting for confounders like age and comorbidities.[](https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.12030408) Similarly, a literature review identified no cases of citalopram-induced sudden cardiac death in patients taking up to 60 mg daily without additional risk factors, questioning the threshold's basis in real-world arrhythmia incidence rather than surrogate QTc changes.[](https://pubmed.ncbi.nlm.nih.gov/22748401/) Critics, including some psychiatrists, argue the FDA's emphasis on ECG abnormalities may exaggerate population-level risks, given citalopram's perceived efficacy at higher doses for treatment-resistant depression, with one analysis estimating 12% of prescriptions exceeded 40 mg pre-warning due to clinical judgment of benefits outweighing theoretical harms.[](https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.13081052) Health Canada issued a parallel advisory in 2012, correlating with reduced prescribing of citalopram and escitalopram (from 44.1% to 22.3% of relevant cases), though without corresponding improvements in dose safety.[](https://www.sciencedirect.com/science/article/abs/pii/S0033318215001528)\n\nOverprescription concerns for citalopram tie into broader antidepressant trends, amplified by its low cost as a generic since 2004 and widespread off-label use for anxiety, insomnia, and pain beyond major depressive disorder. In 2011, U.S. outpatient pharmacies dispensed citalopram to approximately 7.2 million patients, reflecting high-volume utilization amid rising SSRI prescriptions overall.[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related) Post-FDA warning, prescribing patterns shifted toward more ECG monitoring (from negligible to significant increases), but high-dose usage persisted in subsets, with no substantial drop in doses above 20 mg, suggesting incomplete adherence or perceived necessity despite guidelines.[](https://www.psychiatrist.com/pcc/evaluation-changes-citalopram-prescribing-patterns/) Public health advocates have highlighted risks of unnecessary exposure in mild cases, where SSRIs like citalopram show marginal benefits over placebo in meta-analyses, potentially medicalizing normal distress while incurring side effects such as bleeding risks from serotonin-mediated platelet inhibition.[](https://www.ncbi.nlm.nih.gov/books/NBK482222/)\n\nThese issues fuel ongoing debates about regulatory warnings' balance between precaution and evidence-based practice. While FDA actions aimed to mitigate rare but serious cardiac events in a large exposed population, empirical data from large cohorts indicate low absolute arrhythmia rates even at higher doses, prompting calls for personalized risk assessment over blanket limits.[](https://www.thecarlatreport.com/articles/2597-high-dose-citalopram-and-escitalopram-undeserved-bad-rap-) In vulnerable groups, such as the elderly, the warnings underscore public health priorities of minimizing polypharmacy interactions and iatrogenic harm, yet they may inadvertently reduce access to effective therapy for severe depression, where citalopram's role remains substantiated by measurement-based care studies showing response rates up to 50-60% in routine practice.[](https://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.28) Overall, the controversies highlight tensions between pharmacovigilance signals and causal attribution challenges in observational data, with no consensus on whether warnings have optimized net patient safety."])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761887660160,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"[PDF] prescribing information - accessdata.fda.gov\",\"description\":\"is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults (1). -----------------------DOSAGEÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020822s041lbl.pdf\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"[PDF] Celexa Label - accessdata.fda.gov\",\"description\":\"In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects onÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020822s047lbl.pdf\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"Citalopram - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Citalopram hydrobromide exerts its antidepressant action by potentiating serotonergic activity in the central nervous system. Multiple studies confirmed thatÂ ...Continuing Education Activity Â· Indications Â· Mechanism of Action Â· Adverse Effects\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK482222/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"Citalopram: Uses, Interactions, Mechanism of Action - DrugBank\",\"description\":\"Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. Modality: Small Molecule; Groups: Approved,Â ...\",\"url\":\"https://go.drugbank.com/drugs/DB00215\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"Effects of Citalopram and Interpersonal Psychotherapy on ...\",\"description\":\"Citalopram was superior to placebo in reducing depressive symptoms in all efficacy measures. The mean difference between citalopramÂ ...\",\"url\":\"https://jamanetwork.com/journals/jama/fullarticle/205268\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Efficacy of Citalopram in the prevention of recurrent depression in ...\",\"description\":\"Jan 2, 2018 Â· Long-term treatment with citalopram is effective in preventing recurrence of depression in the elderly and is well tolerated.\",\"url\":\"https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/efficacy-of-citalopram-in-the-prevention-of-recurrent-depression-in-elderly-patients-placebocontrolled-study-of-maintenance-therapy/9B8AD15F5345ADE1BFD6DEE7BEA9D187\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"Abnormal heart rhythms associated with high doses of Celexa - FDA\",\"description\":\"Aug 24, 2011 Â· FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).\",\"url\":\"https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"Revised recommendations for Celexa (citalopram hydrobromide ...\",\"description\":\"Dec 15, 2017 Â· In August 2011, FDA issued a Drug Safety Communication (DSC) stating that citalopram should no longer be used at doses greater than 40 mg perÂ ...\",\"url\":\"https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"Citalopram | C20H21FN2O | CID 2771 - PubChem - NIH\",\"description\":\"Citalopram is a Serotonin Reuptake Inhibitor. The mechanism of action of citalopram is as a Serotonin Uptake Inhibitor. See also: Fluoxetine (related);Â ...\",\"url\":\"https://pubchem.ncbi.nlm.nih.gov/compound/Citalopram\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"CITALOPRAM - precisionFDA\",\"description\":\"Chemical Structure ; Stereochemistry. RACEMIC ; Molecular Formula. C20H21FN2O ; Molecular Weight. 324.39 ; Optical Activity. ( + / - ) ; Defined Stereocenters. 0 / 1.\",\"url\":\"https://precision.fda.gov/ginas/app/ui/substances/87ac0121-f698-4b47-b330-7a60e77925f3\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"Stereochemistry in Drug Action - PMC - NIH\",\"description\":\"In the case of citalopram, the S-enantiomer is primarily responsible for antagonism of serotonin reuptake while the R-enantiomer is 30-fold less potent.Missing:  RS | Show results with:RS\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC353039/\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"R-citalopram functionally antagonises escitalopram in vivo and in vitro\",\"description\":\"Since citalopram has a high selectivity for 5-HT reuptake inhibition and R-citalopram has a very low affinity for the serotonin transporter (SERT) (SÃ¡nchez etÂ ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC1574928/\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"Chirality of antidepressive drugs: an overview of stereoselectivity\",\"description\":\"Clinical studies indicate that (S)-citalopram, may have a faster onset than (RS)-citalopram and that the single enantiomer tends to be safer and more effectiveÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10321182/\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Citalopram and Escitalopram Pathway, Pharmacokinetics - ClinPGx\",\"description\":\"Citalopram is a selective serotonin reuptake inhibitor (SSRI). The molecular target for SSRIs is SLC6A4, resulting in an inhibition of serotonin reuptake fromÂ ...\",\"url\":\"https://www.clinpgx.org/pathway/PA164713429\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"[PDF] Citalopram HBr - accessdata.fda.gov\",\"description\":\"The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous systemÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"The mechanism of a high-affinity allosteric inhibitor of the serotonin ...\",\"description\":\"Mar 20, 2020 Â· For S-CIT, it has been proposed that its allosteric binding in SERT contributes to its higher efficacy and faster onset observed in clinicalÂ ...\",\"url\":\"https://www.nature.com/articles/s41467-020-15292-y\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"The allosteric citalopram binding site differentially interferes with ...\",\"description\":\"The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons Â· Abstract Â· MeSH terms.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/27665061/\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"The S-enantiomer of R,S-citalopram, increases inhibitor binding to ...\",\"description\":\"The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotoninÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/15695064/\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Râ€citalopram functionally antagonises escitalopram in vivo and in ...\",\"description\":\"Jan 29, 2009 Â· Since R-citalopram is at least 20-fold weaker than S-citalopram as inhibitor of the 5-HT transporter (SERT) in preclinical studies, the clinicalÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://bpspubs.onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0705738\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"The Pharmacology of Citalopram Enantiomers: The Antagonism by ...\",\"description\":\"Aug 8, 2006 Â· The R-enantiomer is a hypnotic, anticonvulsant, and muscle relaxant, while the S-enantiomer is a convulsant â€“ although the racemate has anÂ ...Abstract Â· Non-clinical studies Â· Allosteric regulation Â· Enantiomers\",\"url\":\"https://onlinelibrary.wiley.com/doi/10.1111/j.1742-7843.2006.pto_295.x\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Citalopram and Escitalopram: A Summary of Key Differences and ...\",\"description\":\"Nov 8, 2023 Â· It is produced as a racemate, meaning it is a mixture of two stereoisomers: R-citalopram and S-citalopram. Escitalopram was approved in 2002 andÂ ...\",\"url\":\"https://psychopharmacologyinstitute.com/publication/citalopram-and-escitalopram-a-summary-of-key-differences-and-similarities-2179/\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"The two enantiomers of citalopram. Citalopram is a racemate\",\"description\":\"The S-enantiomer is responsible for citalopram's effects in inhibiting serotonin reuptake, whereas the R-enantiomer may attenuate this effect through aÂ ...\",\"url\":\"https://www.researchgate.net/figure/The-two-enantiomers-of-citalopram-Citalopram-is-a-racemate_fig1_8546695\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"PharmGKB summary: citalopram pharmacokinetics pathway - PMC\",\"description\":\"This summary briefly reviews the pharmacokinetics of citalopram (Fig. 1) and discusses the candidate pharmacogenes involved.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3349993/\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Multicenter, placebo-controlled, fixed-dose study of citalopram in ...\",\"description\":\"Conclusion: Citalopram was significantly more effective than placebo in the treatment of moderate-to-severe major depression, especially symptoms of depressedÂ ...Missing:  MDD | Show results with:MDD\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10665628/\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"Efficacy and tolerability of citalopram in the treatment of late-life ...\",\"description\":\"These results support the efficacy of citalopram in late-life anxiety disorders. They need to be replicated in a larger study group.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/15625213/\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"Efficacy and Tolerability of Citalopram in the Treatment of Late-Life ...\",\"description\":\"Jan 1, 2005 Â· Our data suggest that citalopram is efficacious in the management of acute anxiety disorders in this age group, as the participants had aÂ ...\",\"url\":\"https://psychiatryonline.org/doi/full/10.1176/appi.ajp.162.1.146\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"The Pharmacologic Treatment of Anxiety Disorders: A Review of ...\",\"description\":\"Jun 11, 2010 Â· A more recent meta-analysis281 showed moderate effect sizes for benzodiazepines that were comparable to those of SSRIs and venlafaxine.\",\"url\":\"https://www.psychiatrist.com/jcp/pharmacologic-treatment-anxiety-disorders-review-progress/\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"Treatment of generalized anxiety disorder with citalopram - PubMed\",\"description\":\"These data suggest that citalopram may be an effective treatment for GAD. Several patients who had failed previous treatment with other SSRIs responded toÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/11981350/\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Treatment of social anxiety disorder with citalopram - ScienceDirect\",\"description\":\"Citalopram appears to be an effective treatment for generalized and performance social anxiety in patients with or without comorbid depression.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0278584601002366\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"Efficacy of treatments for anxiety disorders: a meta-analysis - PubMed\",\"description\":\"In direct comparisons with control groups, all investigated drugs, except for citalopram, opipramol and moclobemide, were significantly more effective thanÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/25932596/\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"OCD: Pharmacotherapy - CAMH\",\"description\":\"There is good Level 1 evidence for all of the SSRIs in OCD (citalopram is off-label for OCD in Canada, although it is indicated in the United States and Europe)Â ...\",\"url\":\"https://www.camh.ca/en/professionals/treating-conditions-and-disorders/ocd/ocd---treatment/ocd---pharmacotherapy\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"Off-label higher doses of serotonin reuptake inhibitors in the ...\",\"description\":\"OLHD-SRIs appear to be safe and well tolerated in OCD patients in SED â‰¤ 650 mg/day doses and the side-effects did not differ between the three dosing groups.\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0010440X24000373\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Clinician's Guide to Medications for PTSD\",\"description\":\"There was insufficient evidence to recommend for or against 3 other SSRIs: citalopram (Celexa), escitalopram (Lexapro), and fluoxetine (Prozac) (1). Note thatÂ ...\",\"url\":\"https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"Pharmacotherapy for Anxiety Disorders: From First-Line Options to ...\",\"description\":\"Jun 17, 2021 Â· In this review, the author examines the evidence for psychopharmacologic treatments among adults for generalized anxiety disorder, panic disorder, and socialÂ ...\",\"url\":\"https://psychiatryonline.org/doi/10.1176/appi.focus.20200048\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"Comparative efficacy and acceptability of 21 antidepressant drugs ...\",\"description\":\"Apr 7, 2018 Â· All antidepressants were more efficacious than placebo in adults with major depressive disorder. Smaller differences between active drugs were found.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/29477251/\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Placebo-controlled comparison of the selective serotonin reuptake ...\",\"description\":\"Results: Both citalopram and sertraline produced significantly greater improvement than placebo on the HAMD, the Montgomeryâ€“Asberg Depression Rating Scale, andÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0006322300009574\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Citalopram versus other antiâ€depressive agents for depression - PMC\",\"description\":\"Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4204633/\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"Efficacy of escitalopram compared to citalopram: a meta-analysis\",\"description\":\"Escitalopram was significantly more effective than citalopram in overall treatment effect, with an estimated mean treatment difference of 1.7 points at week 8.\",\"url\":\"https://academic.oup.com/ijnp/article/14/2/261/696727\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"[Escitalopram is more effective than citalopram for the treatment of ...\",\"description\":\"This study shows that the new SSRI escitalopram has better efficacy in the treatment of severe depression than citalopram, its racemic parent.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/15107719/\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"Evaluation of QTc prolongation and dosage effect with citalopram\",\"description\":\"Our data support the FDA recommendation not to prescribe citalopram in doses greater than 20 mg daily in patients â‰¥60 years old. Given the findings of thisÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6007721/\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"Lack of Efficacy of Citalopram in Children With Autism Spectrum ...\",\"description\":\"Results of this trial do not support the use of citalopram for the treatment of repetitive behavior in children and adolescents with autism spectrum disorders.\u003c|separator|\u003e\",\"url\":\"https://jamanetwork.com/journals/jamapsychiatry/fullarticle/210271\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Escitalopram versus other antidepressive agents for major ...\",\"description\":\"Nov 24, 2023 Â· Escitalopram was superior to other ADs for the acute phase treatment of MDD in terms of efficacy, acceptability and tolerability.\",\"url\":\"https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05382-8\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"Comparative Benefits and Harms of Second-Generation ...\",\"description\":\"Dec 6, 2011 Â· This review compares the benefits and harms of second-generation antidepressants for treating major depressive disorder in adults.\",\"url\":\"https://www.acpjournals.org/doi/10.7326/0003-4819-155-11-201112060-00009\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"European Medicines Agency (EMA)\",\"description\":\"It shows you information on centrally authorised medicines - medicines that EMA evaluated. You can also find information on herbal medicines. Advanced search.\",\"url\":\"https://www.ema.europa.eu/en/medicines\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"Moving beyond first-line treatment options for OCD - PMC\",\"description\":\"SSRIs are first-line pharmacologic treatment options and produce response rates of up to 60% in patients with OCD.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9645290/\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"Off-Label Applications for SSRIs - AAFP\",\"description\":\"Aug 1, 2003 Â· This article reviews the use of SSRIs for six conditions commonly managed by family physicians: generalized anxiety disorder, premature ejaculation, migraineÂ ...Abstract Â· Generalized Anxiety Disorder Â· Diabetic Neuropathy Â· Fibromyalgia\",\"url\":\"https://www.aafp.org/pubs/afp/issues/2003/0801/p498.html\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)\",\"description\":\"FDA- and EMA-approved indications for SSRIs include major depression, generalized anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD), bulimiaÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC9878961/\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Citalopram Dosage Guide + Max Dose, Adjustments - Drugs.com\",\"description\":\"Aug 26, 2025 Â· Usual Adult Dose for Depression: Initial dose: 20 mg orally once a day. Maintenance dose: 20 to 40 mg orally once a day. Maximum dose: 40 mg orally per day.\",\"url\":\"https://www.drugs.com/dosage/citalopram.html\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Celexa (citalopram) dosing, indications, interactions, adverse effects ...\",\"description\":\"Initial dose: 20 mg PO qDay. If needed, may increase to 40 mg/day after at least 1 week. Doses above 40 mg/day are not recommended.\",\"url\":\"https://reference.medscape.com/drug/celexa-citalopram-342958\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Citalopram (oral route) - Side effects \u0026 dosage - Mayo Clinic\",\"description\":\"Sep 30, 2025 Â· This medicine may cause some people to become drowsy, have trouble thinking, or to have problems with movement. Make sure you know how you reactÂ ...\",\"url\":\"https://www.mayoclinic.org/drugs-supplements/citalopram-oral-route/description/drg-20062980\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"[PDF] Celexa (citalopram hydrobromide) Tablets/Oral Solution NDA 20 ...\",\"description\":\"pharmacokinetics of citalopram. Because citalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decreaseÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020822s037%2C021046s015lbl.pdf\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"[PDF] citalopram capsules - accessdata.fda.gov\",\"description\":\"Citalopram dosages above 40 mg once daily are not recommended due to the risk of QT prolongation [see Warnings and Precautions (5.2)]. 2.2 Screen for BipolarÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215428s000lbl.pdf\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"Citalopram 40mg/ml Oral Drops, solution - (emc) | 3349\",\"description\":\"Citalopram Oral Drops have approximately 25% increased bioavailability compared to tablets. ... The oral solution contains 9.0% v/v alcohol (76 mg/ml).\",\"url\":\"https://www.medicines.org.uk/emc/product/3349/smpc\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"[PDF] Citalopram (CipramilÂ®) Oral Drops 40mg/ml\",\"description\":\"Mar 1, 2012 Â· Therefore, citalopram (CipramilÂ®) oral drops have approximately 25% increased bioavailability compared to the tablet formulation. Please beÂ ...\",\"url\":\"https://www.hpft.nhs.uk/media/1942/19-citalopram-tabs-or-drops-equivalent-doses-march-2012.pdf\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Selective serotonin reuptake inhibitors and suicidal behaviour - Nature\",\"description\":\"Sep 24, 2021 Â· The results do not suggest that SSRI-treatment increases the risk for suicidal behaviour in either youths or adults; rather, it may reduce the risk.\",\"url\":\"https://www.nature.com/articles/s41386-021-01179-z\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Risk of suicidality in clinical trials of antidepressants in adults\",\"description\":\"Aug 11, 2009 Â· For a comparison of SSRIs with tricyclics the odds ratios for fatal or non-fatal suicide attempts were 0.886 versus 1.11 (current study).\",\"url\":\"https://www.bmj.com/content/339/bmj.b2880\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Does the initiation of an SSRI for depression increase the risk ... - LWW\",\"description\":\"Evidence-Based Answer. In adults, selective serotonin reuptake inhibitors (SSRIs) have not been shown to increase the risk of completed suicide.\",\"url\":\"https://journals.lww.com/ebp/fulltext/2009/10000/does_the_initiation_of_an_ssri_for_depression.14.aspx\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Suicide risk with selective serotonin reuptake inhibitors and new ...\",\"description\":\"May 19, 2020 Â· Our meta-analysis of observational studies revealed no clear association between exposure to SSRI and suicide risk in patients with depressionÂ ...\",\"url\":\"https://www.medrxiv.org/content/10.1101/2020.05.11.20098178.full\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Efficacy of citalopram in the prevention of recurrent depression in ...\",\"description\":\"Conclusions: Long-term treatment with citalopram is effective in preventing recurrence of depression in the elderly and is well tolerated. Publication types.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/12091260/\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Long-term treatment with citalopram in patients with highly recurrent ...\",\"description\":\"The authors evaluated the efficacy and safety of citalopram in a 28-month study in 48 inpatients with highly recurrent forms of unipolar depression.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/11740983/\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Long term citalopram prevents recurrent depression in the elderly ...\",\"description\":\"Long-term treatment with citalopram prevents recurrence of depression in the elderly and is well tolerated. COMMENTARY. Several studies have foundÂ ...\",\"url\":\"https://mentalhealth.bmj.com/content/6/1/24\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Long-Term Exposure to SSRI Citalopram Induces Neurotoxic Effects ...\",\"description\":\"Aug 19, 2022 Â· Long-term citalopram exposure mainly caused male-specific declines in motor, learning, and memory performance.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/35985052/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Long-Term Exposure to SSRI Citalopram Induces Neurotoxic Effects ...\",\"description\":\"Aug 19, 2022 Â· For F0+ adults, long-term citalopram exposure mainly caused male-specific declines in motor, learning, and memory performance. Analysis ofÂ ...\u003c|separator|\u003e\",\"url\":\"https://pubs.acs.org/doi/abs/10.1021/acs.est.2c01514\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Biochemical and behavioral effects of long-term citalopram ...\",\"description\":\"Long-term SSRI administration to rats reduced the content of 5-HT and its main metabolite shortly after inhibition of 5-HT synthesis in many brain areas withÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/20946930/\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Long-term antidepressant use: patient perspectives of benefits and ...\",\"description\":\"Jul 28, 2016 Â· Common adverse effects included withdrawal effects (73.5%), sexual problems (71.8%), and weight gain (65.3%). Adverse emotional effects, such asÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4970636/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Adverse health outcomes associated with long-term antidepressant ...\",\"description\":\"Sep 29, 2022 Â· Long-term antidepressant use may double the risk of heart disease, finds the most comprehensive epidemiological study to date.\",\"url\":\"https://www.bristol.ac.uk/primaryhealthcare/news/2022/adverse-health-outcomes-associated-with-long-term-antidepressant-use.html\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Antidepressant Withdrawal | Psychiatric News - Psychiatry Online\",\"description\":\"Aug 27, 2025 Â· Systematic reviews estimate the overall incidence of antidepressant withdrawal as ranging from 33% to 56% (Henssler, et al., 2024; Davies \u0026 ReadÂ ...\",\"url\":\"https://www.psychiatryonline.org/doi/10.1176/appi.pn.2025.09.9.1\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor ...\",\"description\":\"Symptoms typically occur within a few days from drug discontinuation and last a few weeks, also with gradual tapering.Missing:  evidence | Show results with:evidence\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/25721705/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"Antidepressant Discontinuation Syndrome: A Meta-Analysis\",\"description\":\"Jul 30, 2024 Â· A liberal estimate is that 15% of patients discontinuing antidepressants will have symptoms, but a much smaller number, around 2%, will have severe symptoms.\",\"url\":\"https://www.jwatch.org/na57759/2024/07/30/antidepressant-discontinuation-syndrome-meta-analysis\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"A review of the management of antidepressant discontinuation ...\",\"description\":\"Strong evidence supports the existence of a discontinuation syndrome following the withdrawal of antidepressant medication, particularly second-generationÂ ...Missing:  citalopram | Show results with:citalopram\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4722507/\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"Maintenance or Discontinuation of Antidepressants in Primary Care\",\"description\":\"Sep 29, 2021 Â· Several systematic reviews of studies have shown a higher rate of relapse among patients who discontinue antidepressant therapy than among thoseÂ ...\",\"url\":\"https://www.nejm.org/doi/full/10.1056/NEJMoa2106356\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"[PDF] An interesting discontinuation syndrome with citalopram: A case report\",\"description\":\"May 11, 2018 Â· BACKGROUND: A group of psychological and psychical symptoms that exist after regular use of selective serotonin re-uptake inhibitor (SSRI).\u003c|separator|\u003e\",\"url\":\"https://www.pulsus.com/scholarly-articles/an-interesting-discontinuation-syndrome-with-citalopram-a-case-report.pdf\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"Incidence of antidepressant discontinuation symptoms - The Lancet\",\"description\":\"Jun 5, 2024 Â· Evidence that about one in 35 patients suffers from severe antidepressant discontinuation symptoms must be considered preliminary at present,Â ...\",\"url\":\"https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2824%2900133-0/fulltext\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"[PDF] citalopram-celexa.pdf - The Good Drug Guide\",\"description\":\"Concomitant use in patients taking monoamine oxidase inhibitors. (MAOIs) is contraindicated (see WARNINGS). Concomitant use in patients taking pimozide isÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020822s29lbl.pdf\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"[PDF] Citalopram 10mg Tablets - Summary of Product Characteristics\",\"description\":\"MAO-inhibitors. The simultaneous use of citalopram and MAO-inhibitors can result in severe undesirable effects, including the serotonin syndrome (see sectionÂ ...\",\"url\":\"https://assets.hpra.ie/products/Human/24269/LicenseSPC_PA1063-017-001_28052013171216.pdf\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"Serotonin Syndrome - StatPearls - NCBI Bookshelf - NIH\",\"description\":\"Mar 2, 2024 Â· SSRIs and tricyclic antidepressants bind SERT, inhibiting their ability to transport serotonin and increasing the amount of serotonin in theÂ ...\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK482377/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Serotonin Syndrome - PMC - PubMed Central\",\"description\":\"Serotonin syndrome is a potentially life-threatening syndrome that is precipitated by the use of serotonergic drugs and overactivation of both the peripheralÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3865832/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Serotonin syndrome caused by interaction between citalopram and ...\",\"description\":\"Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/17381671/\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"An Unusual Case of Serotonin Syndrome with Oxycodone and ...\",\"description\":\"The lung clinic pharmacist suspected a drug interaction between citalopram and oxycodone which had resulted in serotonin syndrome.Missing:  risk | Show results with:risk\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3368298/\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Transient Serotonin Syndrome Caused by Concurrent Use of ...\",\"description\":\"First, the literature suggests that higher plasma concentrations of tramadol and/or SSRIs escalate the risk of serotonin syndrome. Many patients tolerate thisÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4276375/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Citalopram overdose and severe serotonin syndrome in an ...\",\"description\":\"Conclusion. Although rare, single citalopram overdose may be associated with severe serotonin syndrome. Patients with impaired metabolism due to altered enzymeÂ ...Missing:  evidence | Show results with:evidence\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0735675719304176\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"First time, low dose citalopram use-related serotonin syndrome\",\"description\":\"The serotonin syndrome (SS) is one of the rarely observed side-effects of citalopram use. We report a case of SS emerging 3 h after a first time use of low doseÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0161813X0700085X\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Demystifying serotonin syndrome (or serotonin toxicity) - PMC - NIH\",\"description\":\"Some experts report that therapeutic doses of a single drug can cause toxicity, but the risk is low, as it is a dose-related drug toxicity. Serotonin is formedÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6184959/\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Citalopram Overdose: a Fatal Case - PMC - NIH\",\"description\":\"However, citalopram is considered to have the most potential for cardiac and neurologic toxicity among the SSRIs and there are numerous case reports of theseÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4469720/\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"Drug-Induced Serotonin Syndrome - U.S. Pharmacist\",\"description\":\"Nov 17, 2010 Â· A potentially lethal condition, serotonin syndrome (SS) is caused most often when certain antidepressant agents are taken concurrently with other drugs.\",\"url\":\"https://www.uspharmacist.com/article/drug-induced-serotonin-syndrome\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Citalopram (Celexa) Use During Pregnancy - Drugs.com\",\"description\":\"Advice and warnings for the use of Citalopram (Celexa) during pregnancy. FDA Pregnancy Category C - Risk cannot be ruled out.\",\"url\":\"https://www.drugs.com/pregnancy/citalopram.html\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Maternal Use of Specific Antidepressant Medications During Early ...\",\"description\":\"Aug 5, 2020 Â· These studies did not find an increased risk for combined birth defect groups after early pregnancy exposure. An analysis of Nordic populationÂ ...\",\"url\":\"https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2769190\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Antidepressants: Safe during pregnancy? - Mayo Clinic\",\"description\":\"Dec 5, 2023 Â· Most studies show that SSRIs aren't linked with birth defects. But an SSRI called paroxetine (Paxil) might slightly raise the risk of heartÂ ...\",\"url\":\"https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/antidepressants/art-20046420\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy - NIH\",\"description\":\"Oct 1, 2022 Â· A 2020 umbrella review of meta-analyses by Biffi et al. found small but significant associations with SSRIs and risk of preterm birth (RR 1.43,Â ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10590209/\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Selective serotonin reuptake inhibitor use during early pregnancy ...\",\"description\":\"Nov 12, 2018 Â· The aim of this study is to systematically review the associations between SSRIs use during early pregnancy and the risk of congenital malformations.\",\"url\":\"https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1193-5\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Prenatal exposure to selective serotonin reuptake inhibitors and ...\",\"description\":\"Aug 28, 2018 Â· To explore whether exposure to antidepressants during pregnancy increases the risk for persistent pulmonary hypertension of the newborn (PPHN).\",\"url\":\"https://www.ajog.org/article/S0002-9378%2818%2930709-9/fulltext\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"Prenatal Antidepressant Exposure and Child Motor Development\",\"description\":\"Jul 1, 2018 Â· A small increased risk of poorer motor development may exist for children who are exposed to antidepressant medications during pregnancy.\",\"url\":\"https://publications.aap.org/pediatrics/article/142/1/e20180356/37500/Prenatal-Antidepressant-Exposure-and-Child-Motor\",\"favicon\":\"\"},{\"id\":\"93\",\"title\":\"Effects of prenatal exposure to (es)citalopram and maternal ... - Nature\",\"description\":\"May 5, 2023 Â· More ADHD symptoms and delayed communication and psychomotor skills among children exposed to (es)citalopram during pregnancy. Studies haveÂ ...\",\"url\":\"https://www.nature.com/articles/s41398-023-02441-2\",\"favicon\":\"\"},{\"id\":\"94\",\"title\":\"Antidepressant exposure patterns during pregnancy and risk of ...\",\"description\":\"Discontinuing antidepressant use during pregnancy was associated with significant decreased risk of hospitalization compared to continued exposure to CitalopramÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/pii/S0165178124005596\",\"favicon\":\"\"},{\"id\":\"95\",\"title\":\"Citalopram - Drugs and Lactation Database (LactMedÂ®) - NCBI - NIH\",\"description\":\"Feb 15, 2025 Â· Some experts do not recommend citalopram during nursing,[3] but a safety scoring system finds citalopram to be acceptable during breastfeeding.\",\"url\":\"https://www.ncbi.nlm.nih.gov/books/NBK501185/\",\"favicon\":\"\"},{\"id\":\"96\",\"title\":\"Using SSRI antidepressants during breastfeeding â€“ SPS\",\"description\":\"Jan 13, 2023 Â· Most evidence shows that citalopram passes into breast milk in negligible or small amounts (0.7â€“7.9% of the weight-adjusted maternal dose)Â ...\",\"url\":\"https://www.sps.nhs.uk/articles/using-ssri-antidepressants-during-breastfeeding/\",\"favicon\":\"\"},{\"id\":\"97\",\"title\":\"Citalopram | Escitalopram (CelexaÂ® | LexaproÂ®) - MotherToBaby\",\"description\":\"Dec 1, 2024 Â· Citalopram and escitalopram get into breast milk in small amounts. There have been a few case reports of sleepiness and weight loss in infants.\",\"url\":\"https://mothertobaby.org/fact-sheets/citalopramescitalopram-celexalexapro-pregnancy/\",\"favicon\":\"\"},{\"id\":\"98\",\"title\":\"Sertraline, citalopram and paroxetine in lactation - Frontiers\",\"description\":\"Sertraline and paroxetine are the preferred antidepressants during breastfeeding, reaching mostly undetectable infant drug levels.Abstract Â· Introduction Â· Materials and methods Â· Funding\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1414677/full\",\"favicon\":\"\"},{\"id\":\"99\",\"title\":\"Citalopram and breast-feeding: serum concentration and side effects ...\",\"description\":\"The lowest possible effective serum concentration should be used and breast-feeding during the drug absorption phase may be avoided.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/10664835/\",\"favicon\":\"\"},{\"id\":\"100\",\"title\":\"Hormonal mechanism and pathogenetic therapy of citalopram ...\",\"description\":\"Citalopram caused infertility, increased levels of prolactin and corticosterone, and damaged the ovaries histopathologically.\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0890623825000309\",\"favicon\":\"\"},{\"id\":\"101\",\"title\":\"The Effect of Antidepressants on Fertility - PMC - PubMed Central\",\"description\":\"Our data suggest that antidepressants may reduce the probability of a woman with a history of depression to conceive naturally.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4965341/\",\"favicon\":\"\"},{\"id\":\"102\",\"title\":\"Progress in the study of the effects of selective serotonin reuptake ...\",\"description\":\"In addition, the study found that citalopram did not affect sperm quality, although it did cause a significant reduction in sperm production after exposure toÂ ...\",\"url\":\"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1567863/full\",\"favicon\":\"\"},{\"id\":\"103\",\"title\":\"Do Antidepressants Have an Impact on Fertility?\",\"description\":\"Untreated depression or anxiety, but not SSRI antidepressants, appear to negatively impact fertility, reducing rates of pregnancy and live births by about half.\",\"url\":\"https://womensmentalhealth.org/posts/antidepressants-impact-fertility/\",\"favicon\":\"\"},{\"id\":\"104\",\"title\":\"A Randomized, Placebo-Controlled Trial of Citalopram for the ...\",\"description\":\"In conclusion, citalopram treatment significantly improved depressive symptoms compared with placebo within 1 week in this population of children andÂ ...\",\"url\":\"https://psychiatryonline.org/doi/full/10.1176/appi.ajp.161.6.1079\",\"favicon\":\"\"},{\"id\":\"105\",\"title\":\"A Review of Escitalopram and Citalopram in Child and Adolescent ...\",\"description\":\"In conclusion, the available evidence does not support first-line treatment of adolescent depression with either escitalopram or citalopram. It is our opinionÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3222577/\",\"favicon\":\"\"},{\"id\":\"106\",\"title\":\"Comparative efficacy and acceptability of antidepressants ...\",\"description\":\"The aim of this study was to synthesise all the available evidence on commonly used antidepressants, psychotherapies, and their combinations for the acuteÂ ...\",\"url\":\"https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2820%2930137-1/fulltext\",\"favicon\":\"\"},{\"id\":\"107\",\"title\":\"Suicidality in Children and Adolescents Being Treated With ... - FDA\",\"description\":\"Feb 5, 2018 Â· The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants.\",\"url\":\"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications\",\"favicon\":\"\"},{\"id\":\"108\",\"title\":\"The citalopram CIT-MD-18 pediatric depression trial - Sage Journals\",\"description\":\"The published article concluded that citalopram was safe and significantly more efficacious than placebo for children and adolescents, with possible adverseÂ ...\u003c|separator|\u003e\",\"url\":\"https://journals.sagepub.com/doi/10.3233/JRS-160671\",\"favicon\":\"\"},{\"id\":\"109\",\"title\":\"Guidelines for Adolescent Depression in Primary Care (GLAD-PC)\",\"description\":\"Mar 1, 2018 Â· A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry.\",\"url\":\"https://publications.aap.org/pediatrics/article/141/3/e20174082/37654/Guidelines-for-Adolescent-Depression-in-Primary\",\"favicon\":\"\"},{\"id\":\"110\",\"title\":\"CITALOPRAM - Prescriber's Guide â€“ Children and Adolescents\",\"description\":\"May 3, 2024 Â· â—¦ Not specifically approved, but preliminary data suggest citalopram may be safe and effective in children and adolescents with OCD and withÂ ...\",\"url\":\"https://www.cambridge.org/core/books/prescribers-guide-children-and-adolescents/citalopram/263A565EEAEAF8962B276D8763FDC922\",\"favicon\":\"\"},{\"id\":\"111\",\"title\":\"Antidepressants for Pediatric Patients - PMC - NIH\",\"description\":\"The SNRI duloxetine is FDA-approved for treating GAD in children age 7 to 17, but there are no other pediatric indications for duloxetine, or for the otherÂ ...\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6738970/\",\"favicon\":\"\"},{\"id\":\"112\",\"title\":\"[PDF] Treatment of Depression in Children and Adolescents: A Systematic ...\",\"description\":\"The purpose of the review is to examine the benefits and harms of pharmacological and nonpharmacological treatments for child and adolescent depressiveÂ ...\",\"url\":\"https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-224-depression-children-final-report.pdf\",\"favicon\":\"\"},{\"id\":\"113\",\"title\":\"A review of citalopram dose restrictions in the treatment of ...\",\"description\":\"Jul 1, 2019 Â· Citalopram has documented efficacy in several difficult-to-treat geriatric neuropsychiatric disorders. Additionally, treatments for theseÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC6607952/\",\"favicon\":\"\"},{\"id\":\"114\",\"title\":\"Antidepressant use in the elderly is associated with an increased ...\",\"description\":\"We found that SSRIs users were at significantly higher risk for incident dementia when compared to not depressed non-users and also when compared to non-usersÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4760914/\",\"favicon\":\"\"},{\"id\":\"115\",\"title\":\"SSRI toxicity - LITFL\",\"description\":\"Alert and cooperative patients who have ingested \u003e600 mg citalopram or \u003e300 mg escitalopram may have 50 g of activated charcoal within 4 hours after overdose.\",\"url\":\"https://litfl.com/ssri-toxicity/\",\"favicon\":\"\"},{\"id\":\"116\",\"title\":\"Selective Serotonin Reuptake Inhibitor Toxicity Treatment ...\",\"description\":\"Nov 14, 2024 Â· Symptomatic patients with citalopram/escitalopram overdose may require admission to a monitored bed for 24 hours because of the risk ofÂ ...\",\"url\":\"https://emedicine.medscape.com/article/821737-treatment\",\"favicon\":\"\"},{\"id\":\"117\",\"title\":\"Citalopram overdose â€¢ LITFL â€¢ Clinical Case Tox Conundrum\",\"description\":\"Jan 12, 2024 Â· The patient requires cardiac monitoring for a minimum of 13 hours (as the ingested dose is \u003e1000mg, if 600-100mg then 8 hours is sufficient),Â ...Missing:  guidelines | Show results with:guidelines\",\"url\":\"https://litfl.com/citalopram-overdose/\",\"favicon\":\"\"},{\"id\":\"118\",\"title\":\"Did Serendipity Contribute to the Discovery of New Antidepressant ...\",\"description\":\"Apr 28, 2025 Â· Citalopram was synthesized in 1972 by chemist Klaus BÃ¸gesÃ¸ [20] and it was first marketed in Denmark in 1989. Paroxetine, a phenylpiperidineÂ ...\",\"url\":\"https://www.imrpress.com/journal/AP/26/2/10.31083/AP40037/htm\",\"favicon\":\"\"},{\"id\":\"119\",\"title\":\"Our history - Lundbeck\",\"description\":\"This marked the start of Lundbeck's interest in antidepressants that would later lead to the discovery of citalopram, and the development of CipramilÂ®.\u003c|separator|\u003e\",\"url\":\"https://www.lundbeck.com/us/about-us/this-is-lundbeck/our-history\",\"favicon\":\"\"},{\"id\":\"120\",\"title\":\"Citalopram - Molecule of the Month - HTML-only version\",\"description\":\"This molecule was first synthesised in 1972 by the Danish pharmaceutical company Lundbeck [4], who patented the molecule prior to performing clinical trials.\",\"url\":\"https://www.chm.bris.ac.uk/motm/citalopram/citalopramh.htm\",\"favicon\":\"\"},{\"id\":\"121\",\"title\":\"Initial, clinical trial of a new, specific 5-HT reuptake inhibitor ...\",\"description\":\"It is concluded, that citalopram seems to possess antidepressant properties and that controlled trials are wanted to evaluate its therapeutic value as well asÂ ...Missing:  first | Show results with:first\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/6935914/\",\"favicon\":\"\"},{\"id\":\"122\",\"title\":\"The effects of citalopram in single and repeated doses and with ...\",\"description\":\"Gottlieb P, Wandall T, Fredriscon OverÃ¸ K (1980) Initial, clinical trial of a new, specific 5-HT reuptake inhibitor, citalopram (Lu 10â€“171). Acta PsychiatrÂ ...Missing:  early | Show results with:early\",\"url\":\"https://link.springer.com/article/10.1007/BF00606656\",\"favicon\":\"\"},{\"id\":\"123\",\"title\":\"Rise of escitalopram and the fall of citalopram - PMC - NIH\",\"description\":\"Citalopram and escitalopram were FDA-approved for the treatment of major depressive disorder (MDD), and escitalopram is additionally FDA-approved for theÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10197723/\",\"favicon\":\"\"},{\"id\":\"124\",\"title\":\"Citalopram - an overview | ScienceDirect Topics\",\"description\":\"Synthesis of citalopram is proposed to occur by two general routes, usually called the anion strategy and the double Grignard strategy (Scheme 7.12.). Scheme 7Â ...\",\"url\":\"https://www.sciencedirect.com/topics/chemistry/citalopram\",\"favicon\":\"\"},{\"id\":\"125\",\"title\":\"Drug Approval Package:Celexa Tablets (Citalopram Hydrobromide ...\",\"description\":\"Mar 30, 2001 Â· Celexa Tablets (Citalopram Hydrobromide) Company: Forest Laboratories, Inc. Application No.: 20-822. Approval Date: 7/17/1998.\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a.cfm\",\"favicon\":\"\"},{\"id\":\"126\",\"title\":\"[PDF] Celexa (citalopram hydrobromide) 10 mg/5 ml oral solution\",\"description\":\"Mar 27, 2012 Â· Celexa. Generic Name: citalopram hydrobromide. Sponsor: Forest Laboratories, Inc. Approval Date: March 27, 2012. Labeling. Changes: RevisionsÂ ...\",\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021046Orig1s019.pdf\",\"favicon\":\"\"},{\"id\":\"127\",\"title\":\"[PDF] Public Assessment Report\",\"description\":\"Jan 7, 2005 Â· Citalopram has been marketed in EU since 1989 (Denmark), it has ... DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION. January 7Â ...\",\"url\":\"https://ogyei.gov.hu/kiseroirat/ph/ph_0000021931.pdf\",\"favicon\":\"\"},{\"id\":\"128\",\"title\":\"Generic Celexa Availability - Drugs.com\",\"description\":\"Oct 8, 2025 Â· CELEXA (citalopram hydrobromide - tablet;oral) Â· Manufacturer: ABBVIE Approval date: July 17, 1998. Strength(s): EQ 20MG BASE, EQ 40MG BASE, EQÂ ...\",\"url\":\"https://www.drugs.com/availability/generic-celexa.html\",\"favicon\":\"\"},{\"id\":\"129\",\"title\":\"[PDF] Summary of Commission Decision of 19 June 2013 relating to a ...\",\"description\":\"Mar 7, 2015 Â· (4) The agreements were concluded in the context of at least a potential patent dispute (2) between Lundbeck and the generic undertakingÂ ...\u003c|control11|\u003e\u003c|separator|\u003e\",\"url\":\"https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XC0307%2801%29\",\"favicon\":\"\"},{\"id\":\"130\",\"title\":\"[PDF] The Court of Justice dismisses the appeals of a number of ... - CURIA\",\"description\":\"Mar 25, 2021 Â· Once its original compound patent expired, Lundbeck continued to hold only a number of secondary patents which offered more limited protection.\",\"url\":\"https://curia.europa.eu/jcms/jcms/p1_3471475/fr/\",\"favicon\":\"\"},{\"id\":\"131\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.statista.com/statistics/781811/citalopram-prescriptions-number-in-the-us/\",\"favicon\":\"\"},{\"id\":\"132\",\"title\":\"National Prescribing Trends and Cost Analysis of Antidepressants ...\",\"description\":\"Aug 18, 2025 Â· Overall antidepressant prescribing increased by 109% between 2010 and 2023 and anxiolytic prescribing fell by 27% and hypnotic prescribing by 41Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12360015/\",\"favicon\":\"\"},{\"id\":\"133\",\"title\":\"Patterns in (es)citalopram prescriptions to Medicaid and Medicare ...\",\"description\":\"In conclusion, from 2015 to 2020, citalopram use among US Medicaid and Medicare patients has decreased while escitalopram use continues to rise. The use ofÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11919847/\",\"favicon\":\"\"},{\"id\":\"134\",\"title\":\"Evaluation of Changes in Citalopram Prescribing Patterns Following ...\",\"description\":\"Feb 12, 2015 Â· In 2011, the US Food and Drug Administration (FDA) issued a warning with citalopram indicating concerns about the potential for corrected QT (Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4468881/\",\"favicon\":\"\"},{\"id\":\"135\",\"title\":\"Assessing Responsiveness of Health Systems to Drug Safety ...\",\"description\":\"Although trends in high-dose citalopram use declined after the 2011â€“2012 FDA warnings, roughly one-third of older adults still remained on higher thanÂ ...\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S1064748117304736\",\"favicon\":\"\"},{\"id\":\"136\",\"title\":\"Unintended Consequences of Adjusting Citalopram Prescriptions ...\",\"description\":\"The warning was associated with low levels of EKG monitoring, increased anxiolytic and sedative medication use, and higher healthcare utilization.\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/28012712/\",\"favicon\":\"\"},{\"id\":\"137\",\"title\":\"(PDF) Rise of escitalopram and the fall of citalopram - ResearchGate\",\"description\":\"May 8, 2023 Â· Results Overall, a decreasing trend for citalopram and an increasing trend for escitalopram prescription rates were noted in both Medicare andÂ ...\",\"url\":\"https://www.researchgate.net/publication/370609774_Rise_of_escitalopram_and_the_fall_of_citalopram\",\"favicon\":\"\"},{\"id\":\"138\",\"title\":\"Generic Entry, Reformulations, and Promotion of SSRIs - PMC\",\"description\":\"Prozac was the first SSRI to lose patent protection (Table 1). Prozac's patent expired in August 2001 and generic fluoxetine products entered at that time.Â ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC2719790/\",\"favicon\":\"\"},{\"id\":\"139\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.drugpatentwatch.com/p/generic-api/CITALOPRAM%2BHYDROBROMIDE\",\"favicon\":\"\"},{\"id\":\"140\",\"title\":\"Citalopram Market Size, Industry SWOT \u0026 Forecast\",\"description\":\"Rating  4.9  (70) Gain in-depth insights into Citalopram Market, projected to surge from USD 1.2 billion in 2024 to USD 1.8 billion by 2033, expanding at a CAGR of 5.1%.Missing:  Celexa | Show results with:Celexa\",\"url\":\"https://www.verifiedmarketreports.com/product/citalopram-market/\",\"favicon\":\"\"},{\"id\":\"141\",\"title\":\"Evaluation of the FDA Warning Against Prescribing Citalopram at ...\",\"description\":\"A recent Food and Drug Administration (FDA) warning cautioned that citalopram dosages exceeding 40 mg/day may cause abnormal heart rhythms, including torsade deÂ ...\",\"url\":\"https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.12030408\",\"favicon\":\"\"},{\"id\":\"142\",\"title\":\"Citalopram, QTc interval prolongation, and torsade de pointes. How ...\",\"description\":\"We reviewed the literature and found no cases of citalopram-induced sudden cardiac death among patients taking up to 60 mg/day of citalopram and free of riskÂ ...\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/22748401/\",\"favicon\":\"\"},{\"id\":\"143\",\"title\":\"Safety of High-Dosage Citalopram | American Journal of Psychiatry\",\"description\":\"Jan 1, 2014 Â· Clearly, there is a perceived clinical benefit to citalopram dosages above 40 mg/day; 12% of prescriptions in our study exceeded this threshold.\",\"url\":\"https://psychiatryonline.org/doi/10.1176/appi.ajp.2013.13081052\",\"favicon\":\"\"},{\"id\":\"144\",\"title\":\"Health Canada Warning on Citalopram and Escitalopramâ€”Its ...\",\"description\":\"Overall, C-L psychiatrists were less likely to prescribe citalopram/escitalopram following the Health Canada warning, which did not translate into safer dosing.Missing:  controversies | Show results with:controversies\",\"url\":\"https://www.sciencedirect.com/science/article/abs/pii/S0033318215001528\",\"favicon\":\"\"},{\"id\":\"145\",\"title\":\"Evaluation of Changes in Citalopram Prescribing Patterns Following ...\",\"description\":\"Feb 12, 2015 Â· A significantly higher percentage of patients prescribed citalopram underwent ECG monitoring after publication of the FDA warning, thoughÂ ...Missing:  controversies | Show results with:controversies\",\"url\":\"https://www.psychiatrist.com/pcc/evaluation-changes-citalopram-prescribing-patterns/\",\"favicon\":\"\"},{\"id\":\"146\",\"title\":\"High-Dose Citalopram and Escitalopram: Undeserved Bad Rap?\",\"description\":\"Apr 1, 2017 Â· The FDA originally said that high-dose citalopram was â€œcontraindicated,â€ but in 2012 softened its language to â€œnot recommended.â€ However, evenÂ ...\",\"url\":\"https://www.thecarlatreport.com/articles/2597-high-dose-citalopram-and-escitalopram-undeserved-bad-rap-\",\"favicon\":\"\"},{\"id\":\"147\",\"title\":\"Evaluation of Outcomes With Citalopram for Depression Using ...\",\"description\":\"Jan 1, 2006 Â· The authors' primary objectives in this study were to evaluate the effectiveness of citalopram, an SSRI, using measurement-based care in actual practice.\",\"url\":\"https://psychiatryonline.org/doi/full/10.1176/appi.ajp.163.1.28\",\"favicon\":\"\"}],\"images\":[{\"id\":\"74ceb0d9cdd8\",\"caption\":\"Citalopram chemical structure\",\"url\":\"./_assets_/Citalopram_racemic.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"74ceb0d9cdd8\",\"caption\":\"Citalopram racemic structure\",\"url\":\"./_assets_/Citalopram_racemic.svg.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"8270fb30569a\",\"caption\":\"Citalopram metabolism pathway\",\"url\":\"./_assets_/Citalopram_metabolism.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"c730ed0adaac\",\"caption\":\"Citalopram tablets\",\"url\":\"._assets_/Citalopram20-40-2.jpg\",\"position\":\"CENTER\",\"width\":0,\"height\":0},{\"id\":\"8270fb30569a\",\"caption\":\"Citalopram metabolism pathway\",\"url\":\"./_assets_/Citalopram_metabolism.png\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Citalopram\",\"title\":\"Citalopram\",\"content\":\"$1f\",\"description\":\"Citalopram\\n\\nCitalopram chemical structure\\nCitalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S.\",\"metadata\":{\"categories\":[\"Celexa\"],\"lastModified\":\"1761585355\",\"contentLength\":\"75168\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"491711\",\"recentViews\":\"491711\",\"dailyAvgViews\":16390.3671875,\"qualityScore\":1,\"lastViewed\":\"1761887660\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761887660156,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Citalopram\"],\"queryHash\":\"[\\\"page\\\",\\\"Citalopram\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Citalopram\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems. Approved in 1998, citalopram is marketed under the brand name Celexa...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Celexa\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Citalopram\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Citalopram\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems. Approved in 1998, citalopram is marketed under the brand name Celexa...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Citalopram\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Citalopram\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:45.355Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Citalopram\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Its mechanism of action is presumed to involve potentiation of serotonergic activity in the central nervous system through inhibition of serotonin reuptake, with high selectivity and minimal effects on other neurotransmitter systems. Approved in 1998, citalopram is marketed under the brand name Celexa...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="ZGZiNzQzNzMtNGUyZS00MWY0LWE4OTktYzM3MjRkODBhMTJi">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Citalopram\"}]}]\n"])</script></body></html>